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ABSTRACT
ENHANCING THE ANTITUMOR ACTIVITY OF NK-92 NATURAL KILLER CELLS BY
ECTOPIC EXPRESSION OF SODIUM HYDROGEN EXCHANGER 1
Yaoyu Gong
Chi Van Dang

Adoptive cell transfer immunotherapy has remarkable efficacy against some
hematological malignancies. However, its efficacy in solid tumors is limited by the
adverse tumor microenvironment (TME) conditions, most notably that acidity inhibits T
and NK cell mTORC1 activity and impairs cytotoxicity. In several reported studies,
systemic buffering of tumor acidity enhanced the efficacy of immune checkpoint
inhibitors. Paradoxically, we found in a Myc-inducible hepatocellular carcinoma model
that buffering increased tumor mTORC1 activity, negating inhibition of tumor growth by
anti-PD1 treatment. To avoid such adverse effects of systemic buffering favoring tumor
growth, we overexpressed activated RHEB in the human NK-92 cell line, thereby
rescuing acid-blunted mTORC1 activity and enhancing cytotoxicity. To mitigate the effect
of acidity, we sought to metabolically engineer NK-92 cells with ectopically expressed
acid extruder proteins. Whereas ectopic expression of carbonic anhydrase IX (CA9)
moderately increased mTORC1 activity, it did not enhance effector function. In contrast,
overexpressing a constitutively active Na+/H+-exchanger 1 (NHE1; SLC9A1) in NK-92
did not elevate mTORC1 but enhanced degranulation, target engagement, in vitro
cytotoxicity, and in vivo antitumor activity. Our findings provide proof-of-concept that
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metabolic engineering of NK cells can enhance ACT for better efficacy against solid
tumors without increasing mTORC1 activity.
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CHAPTER 1: Backgrounds

1.1: Immunotherapy for solid tumors and natural killer cells
The advancement of cancer immunotherapy has revolutionized the standard of
care for various malignancies, including solid tumors like malignant melanoma and lung
cancer, through the adoption of immune checkpoint blockade (ICB) (Chai et al., 2020).
Further, adoptive cell transfer (ACT), particularly using tumor-infiltrating lymphocytes
(TILs) or chimeric antigen receptors (CARs)-engineered T cells, has also met with
clinical success in treating melanoma or lymphocytic leukemia and lymphoma,
respectively (Neelapu et al., 2017; Rosenberg et al., 2011). However, substantial
numbers of patients remain poorly responsive partly due to biological factors that induce
immunosuppression, limiting the effectiveness of ICB and ACT (Hou et al., 2019).
Additionally, the harsh tumor microenvironment (TME) with low nutrients, hypoxia, and
acidosis also contribute to dysfunctional cytotoxic lymphocytes, rendering them
therapeutically impotent (Dana et al., 2021). Hence, innovations to address the
immunosuppressive biological and TME factors are essential to improving cancer
immunotherapy outcomes. My dissertation focuses specifically on the metabolic
engineering of NK cells to resist the acidic TME and enhance their cytotoxicity against
solid tumors.
Earlier successes were achieved by ICB immunotherapy, which uses monoclonal
antibodies to block inhibitory immune receptors such as CTLA4 and PD1. CTLA4 inhibits
the activation of T cells by competing with the costimulatory receptor CD28 for the
shared ligands, CD80 and CD86 (Walker and Sansom, 2015), while PD1 binds the
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ligand PD-L1 to deliver an inhibitory signal to T cells (Boussiotis, 2016). Both the antiCTLA4 antibody ipilimumab and the anti-PD1 antibody pembrolizumab showed
promising results in clinical trials, where a subset of patients responded profoundly, and
the overall patient survival increased (Hodi et al., 2010; Robert et al., 2015), leading to
their approval by the Food and Drug Administration (FDA) for the treatment of advanced
melanoma in 2011 and 2014, respectively. Similarly, atezolizumab, the antibody
targeting PD-L1, was approved by the FDA for the treatment of urothelial carcinoma and
non-small-cell lung carcinoma (NSCLC) in 2016 (Chang et al., 2021, p. 1). In addition to
the individual targeting of these established checkpoint proteins, recent studies have
tested the combined targeting of multiple checkpoint proteins or emerging immune
checkpoint proteins such as LAG3 (Huang and Zappasodi, 2022). The unprecedented
results obtained by these immunotherapies highlight the potential of empowering
patients' own immune systems to treat cancer.
Compared with ICB, ACT, an emerging immunotherapeutic strategy that first saw
success in treating hematological tumors, has been lagging in treating solid tumors
(Montironi et al., 2021). ACT involves the autologous or allogeneic transfer of TILs or
genetically engineered, tumor-reactive T cells into patients (Kirtane et al., 2021). The
earliest TIL-based ACT scheme for solid tumors consisted of ex vivo expansion of TILs
in resected tumors using the activating cytokine interleukin-2 (IL-2), selection of tumorspecific TILs using autologous tumor cells or human leukocyte antigen (HLA)-matched
tumor cell lines, and infusion of the TILs back to patients with the addition of IL-2
(Rosenberg et al., 2011). While TILs showed promising results in several clinical trials
involving patients with advanced melanoma (Goff et al., 2016; Rosenberg et al., 2011;
2

van den Berg et al., 2020), the time-consuming process of isolation, expansion, and
selection of tumor-reactive TILs has limited its clinical applications (Keilson et al., 2021).
With the advancement of gene-editing techniques such as CRISPR/Cas9,
current ACT can utilize peripheral T cells engineered with receptors targeting specific
tumor antigens, such as T cell receptors (TCRs). Several tumor antigens expressed in
solid tumors, such as New York esophageal squamous cell carcinoma 1 (NY-ESO-1),
melanoma-associated antigen (MAGE)-A3, MAGE-A4, and MART-1, have been targeted
by T cells expressing corresponding TCRs in clinical trials, which showed limited
responses in a small cohort of patients (Kageyama et al., 2015; Morgan et al., 2013,
2006; Robbins et al., 2011). However, the process of selecting potential tumor antigens
for TCR targeting is laborious, involving complicated sequencing and in silico
predictions, followed by extensive validations (Manfredi et al., 2020).
A recent ACT strategy is the use of T cells expressing CARs. CARs allow T cells
to recognize tumor antigens in an HLA-independent manner and enable them to
recognize more extensive target antigens than natural TCRs (Ma et al., 2019). A basic
CAR includes a binding domain for tumor antigens (usually based on the scFv fragment
of the antigen-binding region of a monoclonal antibody), an extracellular hinge domain, a
transmembrane domain, and an intracellular signaling domain (Ma et al., 2019). ACT
trials using anti-CD19 CAR T-cells have achieved remarkable successes in the
treatment of hematological malignancies, such as B-cell acute lymphoblastic leukemia
(B-ALL) and diffuse large B-cell lymphoma (DLBCL), with earlier clinical trials reporting
higher than 80% response rate (Maude et al., 2018; Neelapu et al., 2017). Such
successes led to the FDA approval of CAR T-cell therapy to treat B cell malignancies in
3

2017 and spurred the interest in utilizing CAR T-cells to treat solid tumors. However,
although CAR T-cell therapy has demonstrated remarkable efficacy in patients with
hematological malignancies, it has resulted in an overall low response rate of 9% among
clinical trials for solid tumors such as metastatic melanoma, pancreatic cancer, and
glioblastoma (Hou et al., 2019). Due to the such a limited response rate, the clinical
implementation of CAR T-cell therapy to treat solid tumors is still in its infancy.
Besides T cells, additional attempts have been made to use NK cells or CARmodified NK cells for ACT. NK cells are innate lymphocytes showing cytotoxicity to
tumor cells and virus-infected cells. The NK-mediated killing of target cells is tightly
regulated by the balance of signals from activating and inhibitory NK receptors.
Activating NK receptors, such as NKp30, NKp44, NKp46, and NKG2D, recognize stressrelated cell surface proteins typically induced by viral infections or malignant
transformation (referred to as the "induced self" theory) (Paul and Lal, 2017). While the
tumor-derived ligands of several activating NK receptors have been identified, such as
MICA, MICB, and ULBP1-6 for NKG2D, B7-H6 and BAG6 for NKp30, and PCNA for
NKp44, the ligands of the remaining activating NK receptors remain elusive (Barrow et
al., 2019; Sivori et al., 2019). Inhibitory NK receptors, such as members of the killer cell
immunoglobulin-like receptor (KIR) family, recognize major histocompatibility complex
(MHC) class I molecules. Therefore, cells with missing or aberrantly expressed MHC
class I molecules are recognized by NK cells as targets (the "missing self" theory) (Paul
and Lal, 2017). This theory is supported by studies showing that NK cells preferentially
kill MHC class I-deficient tumor cells (Kärre et al., 1986; Liao et al., 1991; Porgador et
al., 1997; Sottile et al., 2016). Such a feature of NK cells offers them a unique advantage
4

over TILs or TCR-engineered T cells for ACT, as the frequent downregulation of MHC
class I molecules in solid tumors helps the tumors evade T cells but renders them more
susceptible to NK cell-mediated killing (Kageshita et al., 1999; Mendez et al., 2009).
Alternatively, NK cells can recognize and subsequently kill tumor cells by antibodydependent cellular cytotoxicity (ADCC). NK cells express Fc-gamma receptors (FcγR)
that can bind therapeutic antibodies targeting tumor antigens. Studies have shown that
NK cells, at least in part, mediate the antitumor effect of rituximab, the anti-CD20
antibody against B-cell lymphoma (Cartron et al., 2002), and trastuzumab, the antiHER2 antibody against breast cancer (Carson et al., 2001). Besides recognition of target
cells with the help of these receptors, the antitumor activity of NK cells also depends on
cytokines. IL-15 plays an important role in the differentiation and maturation of NK cells,
whereas IL-2, IL-12, IL-15, IL-18, or IL-21 are involved in the activation of NK cells,
resulting in a cytotoxic phenotype (Wu et al., 2017).
The primary mechanism for NK cells to kill target cells involves releasing cytolytic
proteins, such as perforin and granzyme B, stored in specialized lysosomes called lytic
granules, a process termed degranulation (Abel et al., 2018) (Figure 1). During
degranulation, lytic granules travel along the microtubules towards the microtubule
organizing center (MTOC), which is polarized towards the membrane interface between
NK cells and target cells termed immunological synapse (Chen et al., 2007, p. 2, 2006,
p. 2; Hsu et al., 2016). In addition, NK cells can also activate apoptotic signaling in target
cells by presenting ligands of cell surface death receptors, such as Fas ligand, tumor
necrosis factor (TNF), and TRAIL (Paul and Lal, 2017). Finally, NK cells produce
cytokines that antagonize tumor growth, such as interferon (IFN)-γ. Upon binding to
5

receptors on target cells, IFN-γ signals through the JAK/STAT pathway to activate the
transcription of interferon-stimulated genes (ISGs), including the ones encoding proapoptotic proteins caspase 1 and caspase 8 (Chin et al., 1997; Fulda and Debatin,
2002). IFN-γ also potentiates target cell killing mediated by death ligands such as Fas
ligand and TRAIL (Takeda et al., 2002; Xu et al., 1998). As an alternative mechanism to
limit tumor growth, IFN-γ inhibits angiogenesis within tumors by binding to receptors on
vascular endothelial cells, leading to tumor ischemia (Kammertoens et al., 2017).
Earlier successes in using adoptively transferred NK cells to treat hematological
malignancies (Bachanova et al., 2014; Miller et al., 2005) have prompted the use of NK
cells to treat a range of solid tumors in clinical trials. However, adoptively transferred NK
cells in general performed poorly in preclinical studies involving patients with solid
tumors. For example, one study used IL-2-activated autologous NK cells to treat patients
with breast cancer but observed no improvement in survival and relapse (Burns et al.,
2003). A similar study involving patients with metastatic melanoma and renal cell
carcinoma (RCC) found that adoptively transferred autologous NK cells could persist in
the peripheral blood of patients and were relatively well tolerated (Parkhurst et al., 2011).
However, the treatment did not lead to tumor regression. Interestingly, the circulating NK
cells extracted from patients at the end of the study were unable to lyse tumor cells in
vitro, indicating the existence of inhibitory mechanisms limiting the antitumor activity of
these NK cells. It has been argued that autologous NK cells might lack antitumor activity
due to inhibitory signals from matched HLA, and that NK cells from HLA haploidentical
(half-matched) or mismatched donors might show better antitumor activity (Lupo and
Matosevic, 2019). However, the results of clinical trials suggested otherwise. For
6

example, in one study involving patients with recurrent ovarian and breast cancer,
infusion of IL-2-activated, haploidentical NK cells did not result in a clinical response
while causing a few cases of serious side effects (Geller et al., 2011). In another study
involving patients with recurrent, advanced solid tumors, allogenic NK cells from random
donors could not induce a clinical response (Yang et al., 2016). The unsatisfactory
results of NK cell-based ACT trials indicate that there is still room for improvement in the
in vivo antitumor activity of NK cells.
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Figure 1. Schematic representation of natural killer (NK) cell degranulation.
NK cells kill virus-infected or malignantly transformed target cells mainly by releasing
cytolytic proteins stored in lytic granules. Once an NK cell recognizes its target cell, it
establishes a membrane interaction with the target cell called the immunological
synapse (IS). The microtubule organizing center (MTOC) within the NK cell polarizes
towards the IS, leading to the reorganization of the microtubule cytoskeleton. Lytic
granules in the NK cell attach to the microtubule cytoskeleton by motor proteins, which
carry them towards the MTOC positioned to the IS. As a result, the movement of lytic
granules is directed towards the target cell, allowing precise killing of the latter without
damaging bystander cells.
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1.2: The immunosuppressive tumor microenvironment and its acidity
A significant hurdle for ACT in solid tumors is the TME, characterized by its high
level of immunosuppression. The TME of solid tumors contains abundant biological
factors conferring immunosuppression, such as immunosuppressive cells, ligands, and
cytokines. For example, the TME is populated with high numbers of tumor-associated
macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), and T regulatory
(Treg) cells (Labani-Motlagh et al., 2020). The tumor-promoting TAMs secrete the
chemokine CCL22 to attract Treg cells (Curiel et al., 2004), while Treg cells secrete
cytokines such as TGF-β, IL-10, and IL-35 that inhibit the antitumor activity of cytotoxic T
cells (Schmidt et al., 2012). In addition, TAMs also express membrane-bound or soluble
forms of MHC class I molecules such as HLA-E and HLA-G, which are ligands of
inhibitory NK receptors, thereby limiting NK cell cytotoxicity (Kren et al., 2010). MDSCs
express arginase 1 and the inducible nitric oxide synthase (iNOS), generating nitric
oxide (NO) and reactive oxygen species (ROS) to suppress the antitumor activity of both
cytotoxic T cells and NK cells (Gabrilovich and Nagaraj, 2009; Tumino et al., 2021).
These immunosuppressive cells and their products create a hostile environment for
tumor-infiltrating immune cells.
In addition to the biological factors outlined above, the TME also hosts
environmental adversities such as hypoxia, nutrient depletion, and acidosis (Dana et al.,
2021). The abnormal tumor vasculature and the highly active tumor metabolism
contribute to nutrient depletion and hypoxia. Compared with the normal
microvasculature, which is well-organized and highly functional, the tumor
microvasculature is dilated, twisted, heterogeneous, and inefficient at gas and nutrient
9

exchange (Fukumura and Jain., 2007). While solid tumors often activate the formation of
new blood vessels by secreting pro-angiogenic factors such as vascular endothelial
growth factors (VEGFs), the constant pro-angiogenic signaling produces vessels that fail
to mature and organize into functional arterioles, capillaries, and venules, leading to
heterogeneous blood flow and areas of persisting or intermittent nutrient depletion or
hypoxia (Lugano et al., 2020). For example, the average oxygen partial pressure within
malignant melanoma is only about 1/7 that of normal tissue counterparts (Vaupel et al.,
1989). The uncontrolled proliferation of tumor cells, coupled with heightened metabolic
activity, exacerbates the lack of nutrients and oxygen. Faced with these environmental
constraints, tumor cells have evolved strategies to adapt. For example, tumor cells in
hypoxic conditions activate hypoxia-inducible factor (HIF) 1α to drive a predominantly
anaerobic metabolism, elaborated on later (Akakura et al., 2001). When challenged by
shortages of key nutrients such as glucose, tumor cells can shift their metabolism to
consume alternative nutrients such as glutamine (Altman et al., 2016).
Besides the lack of oxygen and nutrients, solid tumors are well documented for
their acidity compared with normal tissues. For example, the extracellular pH (pHe) of
malignant melanoma ranges from 6.4 to 7.3, whereas the pHe of the normal dermis is
7.2 to 7.6; the pHe of sarcoma ranges from 6.2 to 6.9, whereas the pHe of the normal,
resting skeletal muscle is 7.2 to 7.5, as measured by microelectrodes (Vaupel et al.,
1989). The acidic pHe of tumors is mainly a result of the aberrant tumor metabolism that
favors glycolysis over oxidative metabolism (Figure 2) (Böhme and Bosserhoff, 2016).
Glycolysis produces a net of two protons for every glucose consumed. Further, glucose
is converted to pyruvate, which, instead of being shuttled to the mitochondria for
10

oxidative metabolism through the tricarboxylic acid (TCA) cycle, can be converted into
lactic acid, an acidic byproduct, by lactate dehydrogenase A (LDHA) (San-Millán and
Brooks, 2017). This process regenerates NAD+, a cofactor necessary for maintaining
glycolytic flux (Le et al., 2010). Lactic acid is then released to the TME through
transporter proteins such as monocarboxylate transporters (MCTs) 1 and 4 (Pillai et al.,
2019), contributing to extracellular acidification. However, an acidic TME may not be
limited to glycolytic tumors, as tumors lacking key glycolytic enzymes can still acidify
their pHe by hydrating the CO2 produced by the TCA cycle (Helmlinger et al., 2002).
Solid tumors are well documented for their aerobic glycolysis, a phenomenon
termed the Warburg effect, where glycolysis is preferred over oxidative metabolism to
generate energy even in the presence of oxygen (aerobic glycolysis) (Scott et al., 2011).
This shift in metabolism is promoted by signaling pathways downstream of oncogenic
drivers such as BRAF and c-Myc, as well as the loss of the tumor suppressors PTEN
and p53 (Cascone et al., 2018; Parmenter et al., 2014; Stine et al., 2015). Tumors with
mutations of the mitogen-activated protein kinase (MAPK) pathway, such as the
BRAFV600E mutation, have constitutively activated ERK, which drives cell proliferation
and induces transcription factors regulating aerobic glycolysis, including c-Myc, HIF-1α,
and MondoA (Parmenter et al., 2014). c-Myc is known to induce the expression of
glycolytic enzymes, such as LDHA, and glucose transporters, such as glucose
transporter 1 (GLUT1) (Osthus et al., 2000, p. 1; Shim et al., 1997). In addition, c-Myc
binds to the E box motif, which is found in genes encoding multiple proteins involved in
glycolysis, such as hexokinase (HK) 2 and enolase (ENO) 1 (Kim et al., 2004). PTEN is
a negative regulator of the PI3K/Akt signaling pathway, which activates mTORC1, a
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master regulator of cellular metabolism. Loss of PTEN in tumor cells leads to
hyperactivation of mTORC1, driving the expression of glycolytic enzymes such as
pyruvate kinase M2 (PKM2) and phosphoglycerate mutase 1 (PGAM1), potentially
mediated by HIF-1α (Sun et al., 2018, 2011, p. 2). Finally, loss of p53 in tumor cells
promotes a shift from oxidative to glycolytic metabolism due to diminished expression of
synthesis of cytochrome C oxidase 2 (SCO2), a chaperone protein assisting the
formation of the cytochrome C oxidase (COX) complex involved in oxidative
phosphorylation (Matoba et al., 2006). p53 also represses the expression of glucose
transporters (Kawauchi et al., 2008; Schwartzenberg-Bar-Yoseph et al., 2004) while
inducing TIGAR, a negative regulator of glycolysis that lowers the level of fructose 2,6bisphosphate, an allosteric activator of the glycolytic enzymes phosphofructokinase 1
(PFK1) and fructose 1,6-bisphosphatase (FBPase1) (Bensaad et al., 2006).
Additionally, hypoxia within tumors caused by poor perfusion and aberrant tumor
growth stabilizes HIF-1α. Hypoxia arises when oxygen supply in tumors becomes limited
by diffusion due to the combined effect of poorly arranged tumor vasculature (discussed
before) and rapidly increasing tumor size. Studies have shown that locations within solid
tumors about 100 μm away from functional vasculature are typically hypoxic (Helmlinger
et al., 1997). As a transcription factor, HIF-1α upregulates genes encoding key glycolytic
enzymes and glucose transporters, such as HK1, HK2, ENO1, LDHA, GLUT1, and
GLUT3, leading to the metabolic shift to anaerobic glycolysis (Hayashi et al., 2004;
Semenza, 2010; Semenza et al., 1996). In addition to promoting glycolysis, HIF-1α also
negatively regulates oxidative metabolism. HIF-1α promotes the expression of pyruvate
dehydrogenase kinase 1 (PDK1), which phosphorylates and inhibits the TCA cycle
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enzyme pyruvate dehydrogenase (PDH) (Kim et al., 2006). HIF-1α also induces the
expression of BNIP3, leading to mitochondrial autophagy and decreased mitochondrial
respiration (Zhang et al., 2008).
While tumor cells acidify the TME, they typically maintain an alkaline intracellular
pH (pHi) with the help of acid extruder proteins such as MCT1 and MCT4 (Parks et al.,
2013). Besides the MCTs, tumor cells also express carbonic anhydrases (CAs) for the
hydration of CO2, various proton exchangers and pumps for the direct export of H+, and
bicarbonate transporters for the uptake of bicarbonates to neutralize intracellular acids
(Pillai et al., 2019). For example, the Na+/H+-exchanger (NHE) protein NHE1 exports H+
using a Na+ gradient. NHE1 is expressed and activated in solid tumors such as
malignant breast cancer and was thought to promote tumor proliferation and migration
while contributing to the acidic TME (Busco et al., 2010). The plasma membrane
vacuolar-type ATPase (V-ATPase) pumps out H+, a process coupled to ATP hydrolysis.
It was reported that plasma membrane V-ATPase helped maintain an alkaline cytosolic
pH of breast cancer cells while promoting local acidification of their surroundings, an
effect thought to promote tumor cell invasion (Cotter et al., 2015). The expression of
these acid extruder proteins in tumor cells is often induced by metabolic conditions cooccurring with acidosis, such as hypoxia. Imaging experiments have demonstrated a
correlation between the diminishing presence of oxygen further away from tumor
vasculature and the increasing acidity (Helmlinger et al., 1997). As a potentially
protective mechanism, the plasma membrane carbonic anhydrase CA9 is upregulated
by HIF-1α to counteract intracellular acidosis (Chiche et al., 2008). Hypoxia also
upregulates MCT4 in a HIF-1α-dependent mechanism (Ullah et al., 2006, p. 4). The
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collective action of these acid extruder proteins enables tumor cells to thrive in the acidic
TME while further acidifying it.
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Figure 2. Schematic representation of the pathways in tumor cells contributing
to the acidic tumor microenvironment (TME).
The acidic TME of solid tumors such as melanoma is mainly a result of aberrant
glycolysis of tumor cells and surrounding stromal cells. Within tumor cells, the
activation of tumorigenic pathways, such as c-Myc, ERK (as in BRAF-mutated
tumors), and PI3K (as in PTEN-mutated tumors), leads to elevated aerobic glycolysis
(Warburg effect). Hypoxia, a result of poor perfusion, also drives anaerobic glycolysis.
The high level of glycolysis leads to the accumulation of lactic acid, an acidic byproduct that is exported by tumor cells with the help of a group of acid extruder
proteins including but not limited to monocarboxylate transporters (MCTs) and proton
transporters (such as Na+/H+-exchanger 1, or NHE1). Besides direct export, the
intracellular lactic acid produced by glycolysis can also be neutralized by intracellular
bicarbonate to produce carbon dioxide (CO2), a gaseous acid equivalent that can
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diffuse freely across the plasma membrane. Additional CO2 can be generated by the
tricarboxylic acid (TCA) cycle in tumor cells undergoing oxidative metabolism. Once
outside cells, CO2 is converted back to bicarbonate and proton by extracellular
carbonic anhydrases (such as CA9), thereby achieving indirect export of intracellular
acids. Some of these acid extruder proteins, such as CA9, are upregulated by hypoxia
as a potentially protective mechanism for tumors to survive the ensuing acidosis.
Overall, these pathways help tumor cells to maintain a relatively stable or alkaline pHi
while acidifying their surroundings.
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1.3: Effect of acidity on immune effector cells
Although tumor cells are protected from acidosis with the help of acid extruder
proteins, the infiltrating immune effector cells in the TME are vulnerable to acidity, partly
due to their lack of acid extruder proteins (Huber et al., 2017). This observation has
important implications as a growing body of research has suggested that immune
effector cells, including CD8+ T cells and NK cells, lose their antitumor cytotoxicity in
acidic conditions in vitro. For example, primary mouse or human CD8+ T cells lose
cytokine production and antitumor cytotoxicity in acidic culture media (Bosticardo et al.,
2001; Brand et al., 2016; Calcinotto et al., 2012; Fischer et al., 2007; Haas et al., 2015;
Mendler et al., 2012, p. 38; Nakagawa et al., 2015; Pilon-Thomas et al., 2016; Wu et al.,
2020). Similarly, primary mouse and human NK cells also show diminished effector
activity and expression of activating NK receptors in acidic environments (Brand et al.,
2016; Fischer et al., 2000; Harmon et al., 2019; Husain et al., 2013; Loeffler et al., 1991;
Pötzl et al., 2017). In both cases, the presence of lactate is not necessary to inhibit the
cytotoxicity of the effector cells, as acidification caused by inorganic acids, such as
hydrochloric acid, is sufficient.
Although the exact mechanism for immune effector cells to sense the acidic
environment remains unclear, previous studies have otherwise suggested several
possibilities for how acidity impairs the effector function of these cells. First, acidity may
alter the metabolism of immune effector cells, leading to a shift from glycolytic to
oxidative metabolism (Heintzman et al., 2022). Although utilizing glycolysis and oxidative
phosphorylation for energy, cytotoxic T and NK cells have a primarily glycolytic
metabolic phenotype (O’Brien and Finlay, 2019). It has been shown that T cells within
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the acidic niche of lymph nodes have reduced glycolysis due to acid inhibition of MCTs
and the subsequent negative feedback to the glycolytic flux (Wu et al., 2020). However,
it is unclear whether the inhibition of glycolysis due to tumor acidity can affect the
effector function of NK cells. Second, acidity may blunt intracellular signaling pathways
involved in effector functions. Lactic acid was shown to block the expression of nuclear
factor of activated T cells (NFAT) in T and NK cells downstream of TCR or activating NK
receptors, which caused diminished secretion of the antitumor cytokine IFN-γ (Brand et
al., 2016). It also impaired TCR-triggered phosphorylation of MAPKs p38 and JNK in T
cells, which was believed to cause decreased T cell degranulation (Mendler et al., 2012).
Third, acidity may upregulate immune checkpoint proteins that inhibit immune cell
function. For example, VISTA, an immune checkpoint protein that suppresses T cell
effector function, is upregulated by acidity and is overexpressed in the TME (Johnston et
al., 2019). Similarly, low pH has also been shown to upregulate the checkpoint receptor
CTLA4 in T cells (Bosticardo et al., 2001). While primary human NK cells have been
reported to express both VISTA and CTLA4 (Lanuza et al., 2020), whether their
induction by tumor acidity plays a role in inhibiting their intratumoral function remains
unclear.
While there is limited direct evidence suggesting that tumor acidity impairs the
antitumor activity of tumor-infiltrating immune cells in vivo, two observations provide
indirect support for this theory. First, it has been observed that increased tumor
glycolysis is correlated with resistance to immunotherapies such as ACT. In a melanoma
mouse model, overexpression of glycolytic genes impaired the ability of adoptively
transferred T cells to kill tumor cells, an effect thought to be partly mediated by lactic
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acidosis in the TME (Cascone et al., 2018). Increased expression of genes related to
glycolysis has also been observed in tumor tissues of melanoma and leukemia patients
not responding to ACT (Cascone et al., 2018; Fraietta et al., 2018). Second, researchers
have developed several strategies to neutralize tumor acidity over the past decade, and
some of these strategies could enhance the efficacy of immunotherapies such as ICB
and ACT. These strategies will be elucidated in the next section.
Besides directly affecting the function of immune effector cells, acidity can
indirectly interfere with the function of these cells by activating suppressor cells. For
example, tumor acidity has been shown to promote the anti-inflammatory M2
polarization of TAMs, suppressing the effector function of both T cells and NK cells
(Bohn et al., 2018; Colegio et al., 2014). Low pH also activated the expression of iNOS
in macrophages through a mechanism mediated by nuclear factor-κB (NF-κB) (Bellocq
et al., 1998), potentially contributing to immunosuppression by increased production of
NO. Unlike cytotoxic T cells, whose effector functions are impaired in the acidic TME, the
immunosuppressive Treg cells thrive in the TME due to their ability to utilize lactic acid as
an alternative energy source (Wang et al., 2020, p. 36; Watson et al., 2021). Such
metabolic plasticity might be enabled by CD36-mediated upregulation of peroxisome
proliferator-activated receptor-β (PPAR-β), enhancing mitochondrial functions (Wang et
al., 2020, p. 36). These immunosuppressive cells may contribute to the inhibition of
immune effector cells within the acidic TME.
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1.4: Current strategies to target tumor acidity
Due to the substantial evidence suggesting that the acidic TME inhibits the
antitumor activity of immune effector cells, researchers have developed several
strategies to target tumor acidity, with the ultimate goal of enhancing the efficacy of
immunotherapies.
One such strategy is to inhibit the acid production pathways in tumor cells. For
example, therapeutics may restrict glycolysis in tumor cells to reduce lactic acid
production. In theory, this approach can reinvigorate acid-blunted immune effector cells
while "starving" tumor cells. Previously, genetic deletion of LDHA and LDHB in mouse
melanoma cell lines increased the pH of tumor xenografts and potentiated the effect of
checkpoint blockers anti-PD1 and anti-CTLA4 antibodies, providing a theoretical
framework for such an approach (Renner et al., 2019). Recently, a study showed that
therapeutic inhibition of LDHA by oxamate enhanced the efficacy of anti-PD1 antibody in
a CD8+ T cell-dependent manner in an NSCLC humanized mouse model (Qiao et al.,
2021). However, such a strategy raises concerns as cytotoxic T cells mainly undergo
glycolytic metabolism upon activation. Indeed, treatment of CD8+ T cells with the
glucose analog 2-deoxy-D-glucose (2DG), a glycolysis inhibitor, blocked the
upregulation of cytolytic proteins perforin and granzyme B upon activation but promoted
memory cell differentiation (Sukumar et al., 2013). Further, LDHA was shown to mediate
the expression of IFN-γ in T cells, and genetic ablation of LDHA in T cells rescued mice
from a fatal autoimmune disease, revealing the potentially unwanted consequence that
systemic inhibition of glycolysis may harm cytotoxic T cells in the TME (Peng et al.,
2016). Similarly, blocking glycolysis in NK cells with 2DG diminished the expression of
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effector molecules IFN-γ and granzyme B (Donnelly et al., 2014) and impaired their
cytotoxicity against virus-infected target cells (Mah et al., 2017). Genetic deletion of
LDHA in NK cells impaired their effector function against both virus-infected and tumor
cells (Sheppard et al., 2021). In addition, the aberrant expression of FBP1, a negative
regulator of glycolysis, led to decreased cytotoxicity and viability of NK cells in a Krasdriven lung cancer mouse model (Cong et al., 2018). In conclusion, these findings
indicate that the systemic blockade of glycolysis may be detrimental to tumor-infiltrating
immune effector cells and that the risks and benefits of such strategies need to be
carefully evaluated on a case-by-case basis.
Besides restricting glycolysis, blocking acid export of tumor cells via acid extruder
proteins represents another strategy to reduce tumor acidosis. As described in prior
sections, tumor cells utilize MCT1 and MCT4 to export lactic acid. Diclofenac, a nonsteroidal anti-inflammatory drug (NSAID) that also inhibits MCT1 and MCT4, could
increase tumor pH, augment the efficacy of anti-PD1 antibody, and increase interferon
IFN-γ production by CD8+ T cells and NK cells in a mouse melanoma model (Renner et
al., 2019). Besides the MCTs, others have targeted the proton pump H+/K+-ATPase with
inhibitors such as esomeprazole. Previously, studies have shown that inhibiting H+/K+ATPase in mouse melanoma cells with esomeprazole led to reduced proliferation and
survival, an effect that was potentiated by incubating the cells in acidic culture media (De
Milito et al., 2010). Further, treatment of melanoma-bearing mice with esomeprazole led
to increased pHe and decreased pHi of the tumors with reduced tumor growth,
suggesting that esomeprazole might negate the advantage of tumor cells within the
acidic TME by blocking their acid extrusion via H+/K+-ATPase. As a result, others have
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combined immunotherapy with esomeprazole for solid tumors and found synergistic
effects. For example, treating a melanoma mouse model with esomeprazole enhanced
the efficacy of subsequent ACT with T cells (Calcinotto et al., 2012). However, multiple
meta-analyses have suggested that the concomitant proton pump inhibitor use has an
overall negative impact on the efficacy of immune checkpoint inhibitors in clinical trials
involving patients with solid tumors, evidenced by tumor progression and decreased
survival of patients (Li et al., 2020; Qin et al., 2021; Rizzo et al., 2022). While the exact
mechanism for this negative correlation is unclear, studies have proposed that PPIs
might modify the efficacy of ICB by altering the gut microbiome (Chalabi et al., 2020),
which is known to modulate immune cell functions (Schluter et al., 2020).
Since the inhibition of glycolysis or acid export might negatively affect the
function of tumor-infiltrating immune effector cells, researchers have developed an
alternative strategy to target the acidic TME – systemic buffering. The most studied
method involves feeding experimental animals orally with sodium bicarbonate (NaHCO3)
solution (Robey et al., 2009). NaHCO3 increases blood pH by neutralizing acid as a
base, increasing tumor pH. It has been shown that NaHCO3 alone could inhibit
spontaneous metastasis in a mouse model of metastatic breast cancer (Robey et al.,
2009). Moreover, such a method has successfully boosted the efficacy of cancer
immunotherapies, including ICB and ACT. For example, it was shown that systemic
buffering by oral sodium bicarbonate (NaHCO3) enhanced the effector functions of
immune cells, including NK cells and T cells, in mice (Pilon-Thomas et al., 2016; Pötzl et
al., 2017). Moreover, systemic buffering in a melanoma mouse model boosted the
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response to immunotherapies, including ICB and ACT with T cells, leading to complete
remission in some animals (Pilon-Thomas et al., 2016).
1.5: Significance of the study
Despite the successes of the systemic neutralization strategies to tackle tumor
acidosis, it remains possible that systemic buffering may unexpectedly benefit tumor
cells by relieving the negative impact of acidosis on them. Indeed, many clinical trials of
immune checkpoint inhibitors with concomitant PPIs reported mixed results, with an
overall deleterious effect evidenced by increased disease progression and death of
patients (Qin et al., 2021). In addition, we found that systemic alkalization by oral
NaHCO3 negated the effect of anti-PD1 antibody, an immune checkpoint inhibitor, in an
inducible c-Myc-driven mouse hepatocellular carcinoma (HCC) model. This result could
be attributed to the activation of tumor mTORC1, a known driver of murine HCC (Menon
et al., 2012), by systemic buffering.
Therefore, instead of neutralizing tumor acidity systemically, we focused on
targeted engineering of immune cells as an alternative approach to mitigate the
inhibitory effect of the acidic TME on immune cells. Using the human NK cell line NK-92
as a model of immune effector cells, we first demonstrated the feasibility of our
metabolic engineering approach by overexpressing a constitutively active RHEB, which
rescued the acid-blunted mTORC1 activity (Walton et al., 2018) and enhanced the
cytolytic activity of the cells. We then sought to generate acid-resistant NK-92 cells by
overexpressing acid extruder proteins CA9 or NHE1. While CA9 could not alkalinize the
pHi of NK-92 cells, we found that NHE1 enhanced the antitumor activity of NK-92 cells in
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vitro and in vivo by enhancing their degranulation. These findings demonstrate the
feasibility of metabolic engineering immune cells to overcome inhibition in the TME.
Furthermore, the metabolic engineering approach can potentially be combined with ACT
to enhance its efficacy against solid tumors, where the TME is a significant cause of
immune inhibition.
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CHAPTER 2: Materials and Methods
2.1: Cell culture and media
NK-92 cells (Gong et al., 1994) and NK-92MI cells (Tam et al., 1999) were
purchased from the ATCC (CRL-2407 and CRL-2408). Cells were maintained in a
custom culture media based on a previously described formulation (Kotzur et al., 2022):
RPMI 1640 with 25 mM HEPES (Corning, 10-041-CV) supplemented with 10% fetal
bovine serum (FBS) (GeminiBio, 900-108), sodium pyruvate (1 mM), L-glutamine (2
mM), MEM Non-Essential Amino Acids (1×) (Gibco, 11140-050), and 2-mercaptoethanol
(2×) (Gibco, 21985-023). In addition, for NK-92 cells, 300 IU/ml of recombinant human
IL-2 (STEMCELL Technologies, 78036) was added prior to use.
Human melanoma cell lines WM3629, WM4237, and WM1727A (Li et al., 2017)
were gifts from Dr. Meenhard Herlyn at the Wistar Institute. K562 cells were purchased
from ATCC (CCL-243). Both melanoma cells and K562 cells were maintained in RPMI
1640 with 25 mM HEPES supplemented with 5% FBS.
pH-controlled culture media for NK-92 cells were prepared following a previously
reported method that considered acidification of the media in incubators with 5% CO2
(Michl et al., 2019). Briefly, the media stock was prepared using complete NK-92 culture
media plus 20 mM HEPES and 20 mM PIPES and adjusted to the desired pH using
concentrated NaOH or HCl solutions. NaHCO3 was added at 18, 11.4, 7, 4.3, 2.7, and
0.8 mM for pH 7.4, 7.2, 7.0, 6.8, 6.6, and 6.3 media, respectively, as determined by a
titration process described in the cited work. The varying amount of NaHCO3 ensures
that the media maintain their desired pH in incubators with 5% CO2, as media with high
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pH tend to absorb CO2 when placed in a CO2-rich gas environment. We chose the pH
range of 6.3 to 7.4 for pH-controlled media used in this study based on the reported
extracellular pH range of malignant melanoma (Vaupel et al., 1989).
2.2: Stable overexpression
The lentiviral vector encoding constitutively active human RHEB was generated
by cloning the RHEBN153T cDNA of the plasmid pcDNA3-FLAG-Rheb-N153T (Addgene,
19997), a kind gift from Dr. Fuyuhiko Tamanoi (Urano et al., 2005), into pHIG2PW
(Figure 3), a lentiviral transfer vector gifted by Dr. Xin He at the University of
Pennsylvania. Besides encoding the transgene, the transfer vector also has bicistronic
expression of EGFP-P2A-puro. Lentiviral vectors encoding human CA9 and
constitutively active human NHE1 (gene symbol SLC9A1) were generated by cloning
synthesized human CA9 cDNA and codon-optimized human NHE1 cDNA with mutated
histidine clusters (Webb et al., 2016) into pHIG2PW mentioned before. The codonoptimized constitutively active NHE1 (Table 1) was synthesized (GeneCopoeia) with 5'
Notl restriction site and Kozak consensus sequence as well as 3' XbaI site subcloned
into the Gateway PLUS shuttle vector. The lentiviral vector encoding inactive mutant
NHE1 bearing E262I mutation was generated by site-directed mutagenesis of the
constitutively active NHE1 vector using Q5 Site-Directed Mutagenesis Kit (New England
Biolabs, E0554S) with custom primers: 5'-CGTTTTCGGTATCAGTCTTCTCAATG-3' and
5'-AGTATATGAAGAAGTTCGTTG-3'. The lentiviral vector encoding human SERPINB9
was generated by cloning the SERPINB9 cDNA from a human ORF clone (GenScript,
OHu01596) into pHIG2PW. The lentiviral vector encoding human MCT4 (gene symbol
SLC16A3) was made by cloning the codon-optimized human MCT4 ORF from
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pDONR221_SLC16A3 (Addgene, 131899), a kind gift from the RESOLUTE Consortium
and Dr. Giulio Superti-Furga, to pHIG2PW.
All lentiviruses were packaged by co-transfecting the transfer plasmids with
second-generation packaging and envelope plasmids pMD2.G and psPAX2, gifts of Dr.
Didier Trono (Addgene, 12259 and 12260). Lentiviruses were purified and concentrated
by high-speed centrifugation using a sucrose cushion as described before (Jiang et al.,
2015) and were used to transduce NK-92 or NK-92MI cells. Briefly, NK-92 or NK-92MI
cells were stimulated with 500 IU/ml of recombinant human IL-2 (STEMCELL
Technologies, 78036) and 50 ng/ml of recombinant human IL-21 (R&D Systems, 8879IL-010) overnight prior to the addition of concentrated lentiviruses. Cells were incubated
with lentiviruses for four days, followed by media change and puromycin selection (2
ug/ml) for two weeks. Drug resistant cells were further sorted by EGFP using a cell
sorter.
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Table 1. Nucleotide sequence of codon-optimized, constitutively active human
NHE1 cDNA.
Highlighted nucleotides denote the arginine residues mutated from the proton-sensing
histidine residues in the wild-type NHE1 cDNA to confer constitutive activation.
ATGGTGCTGAGGAGTGGTATCTGCGGCCTGTCCCCCCATAGGATATTTCCAAGTTTGCTTGTAGTTGTA
GCTCTCGTCGGATTGCTCCCTGTTCTGCGCTCTCACGGACTGCAACTGTCTCCGACTGCTTCCACTATT
CGGTCATCTGAGCCACCGCGCGAGAGGAGCATCGGGGATGTTACTACAGCACCACCAGAGGTCACCCCC
GAGTCACGACCAGTGAACCACTCCGTCACTGATCATGGGATGAAGCCGCGGAAGGCTTTCCCCGTGCTC
GGGATTGATTACACGCATGTACGGACACCTTTTGAAATCTCACTCTGGATCCTGTTGGCGTGTCTCATG
AAAATCGGGTTTCATGTAATACCGACGATTTCTTCCATCGTGCCAGAGTCTTGTCTCCTCATTGTGGTC
GGTCTCCTCGTTGGCGGTCTCATCAAGGGAGTTGGCGAGACACCGCCGTTTTTGCAATCAGATGTATTC
TTTTTGTTTCTTCTGCCCCCAATAATTCTTGATGCAGGGTATTTCTTGCCGCTCAGACAGTTTACTGAG
AACCTTGGGACTATACTTATATTCGCGGTAGTAGGAACCCTCTGGAACGCCTTTTTCCTGGGAGGGTTG
ATGTACGCTGTATGTCTCGTCGGTGGAGAGCAAATTAACAATATTGGTCTGTTGGACAATCTTTTGTTC
GGCTCCATAATCAGCGCTGTCGATCCAGTCGCCGTGCTCGCTGTATTCGAGGAAATCCACATCAACGAA
CTTCTTCATATACTCGTTTTCGGTGAAAGTCTTCTCAATGATGCCGTGACTGTAGTTCTTTACCATCTC
TTCGAAGAGTTCGCCAACTATGAGCACGTTGGAATAGTCGATATTTTCCTTGGGTTTCTCTCTTTCTTC
GTCGTTGCCCTCGGAGGAGTCTTGGTAGGCGTCGTCTACGGCGTCATAGCAGCCTTTACTTCTAGGTTT
ACGTCTCACATACGCGTGATTGAGCCGTTGTTTGTTTTTCTGTATTCCTATATGGCCTATTTGAGTGCC
GAGCTTTTTCATCTTAGCGGTATAATGGCCCTTATCGCGTCTGGGGTTGTCATGCGCCCATATGTCGAG
GCGAATATAAGTCACAAATCCCATACCACGATTAAATATTTCCTCAAAATGTGGTCAAGCGTTTCAGAA
ACCCTTATATTCATATTCCTGGGAGTCAGCACAGTAGCGGGCTCCCATCACTGGAACTGGACATTCGTA
ATATCTACGTTGCTCTTTTGCCTGATAGCCAGAGTTCTGGGCGTGCTCGGACTGACTTGGTTTATTAAC
AAATTCAGAATTGTTAAACTGACGCCTAAAGACCAGTTCATCATAGCATATGGAGGTTTGCGCGGGGCA
ATCGCATTCAGTCTGGGGTATCTCCTCGACAAGAAGCACTTCCCCATGTGCGATCTGTTTTTGACCGCG
ATCATCACAGTCATATTTTTTACGGTTTTTGTACAGGGGATGACCATCAGGCCACTCGTTGATCTTTTG
GCGGTCAAAAAAAAACAAGAGACGAAACGAAGTATAAATGAAGAGATACATACTCAGTTCTTGGACCAC
TTGCTGACCGGGATAGAGGACATTTGTGGCCGCTATGGCAGGCGACGATGGAAGGATAAACTGAATCGG
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TTTAACAAAAAATATGTGAAAAAATGCTTGATCGCCGGGGAACGGTCTAAAGAACCACAGCTTATAGCC
TTCTATCATAAAATGGAGATGAAGCAGGCGATAGAGCTGGTGGAATCCGGAGGAATGGGAAAGATACCC
AGCGCTGTCTCAACCGTGTCTATGCAAAATATCCATCCGAAGTCCCTTCCATCTGAGCGAATCCTGCCC
GCCCTCAGCAAGGACAAAGAGGAGGAGATTCGGAAAATTCTGAGGAATAACTTGCAGAAGACTAGACAG
CGCCTCAGATCCTATAACCGACACACCCTGGTGGCCGACCCCTATGAGGAAGCCTGGAACCAGATGTTG
CTTCGACGGCAAAAAGCTCGACAATTGGAGCAAAAGATCAATAACTATCTCACCGTCCCTGCTCACAAA
CTTGACTCTCCCACTATGTCTCGAGCCAGGATAGGATCTGACCCCCTGGCGTACGAGCCAAAAGAGGAT
TTGCCTGTCATTACGATAGATCCGGCCTCCCCGCAGTCTCCCGAGTCCGTAGACCTGGTTAACGAGGAA
CTTAAGGGCAAAGTTCTGGGCCTTAGTCGGGATCCGGCAAAGGTTGCTGAGGAGGACGAAGATGATGAT
GGGGGTATTATGATGAGGTCAAAAGAAACAAGTTCCCCCGGTACGGACGATGTATTCACGCCGGCGCCT
TCTGACTCCCCAAGCTCTCAACGCATACAGCGGTGCCTGAGTGACCCGGGGCCCCATCCGGAGCCGGGT
GAAGGGGAGCCGTTTTTTCCTAAAGGCCAATAG
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Figure 3. Schematic of the pHIG2PW lentiviral cloning vector.
pHIG2PW is a custom second-generation lentiviral expression vector allowing EF1α
promoter-driven transgene expression, with concomitant, internal ribosome entry site
(IRES)-driven expression of EGFP and puromycin resistance gene for the selection of
positively transduced cells.
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2.3: Animal studies
All animals were kept in a specific pathogen-free facility at the Wistar Institute
and provided drinking water and food ad libitum. Littermates were randomized before
each experiment.
To study the effect of systemic alkalization on the efficacy of checkpoint blockade
immunotherapy, LAP/MYC transgenic mice, which develop c-Myc-driven neonatal
hepatocellular carcinoma unless treated with doxycycline (Beer et al., 2004), were
obtained from Dr. Dean Felsher at Stanford University and bred at Charles River
Laboratory. In these animals, the inducible MYC allele was integrated into an autosome,
and animals were maintained in the homozygous states of the activator LAP (Tet-Off) or
MYC. Animals were bred on demand to generate compound heterozygotes of LAP and
MYC and then shipped for experiments. Experiments using LAP/MYC mice were
performed using male and female mice at four to six weeks of age. Mice were provided
with regular or NaHCO3-containing (200 mM) drinking water and were fed with regular or
doxycyclin-containing (200 mg/kg) chow diet. To study the effect of systemic alkalization
on the efficacy of immune checkpoint blockade, mice were treated with either 12 mg/kg
of GoInVivo purified anti-mouse CD279 (PD1) antibody (BioLegend, 135235) or isotype
control antibody (BioLegend, 400564) via intraperitoneal injection. Mouse livers were
dissected and weighed at the endpoint of the experiment as a surrogate of tumor weight.
To test the in vivo cytotoxicity of NHE1-expressing NK-92MI cells, we used an
adoptive transfer model based on one used in Dr. Steven Albelda's lab. Female NSG
mice of nine to twelve weeks of age were obtained from the Animal Facility at the Wistar
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Institute. WM3629 xenografts were generated by subcutaneously injecting 3 × 105 cells
in a 1:1 mixture of PBS and Matrigel Growth Factor Reduced (Corning, 354230) at the
flanks of the mice. Once the xenografts reached a volume of 100 mm3, a size readily
detectable by caliper measurement, 2.5 × 106 NK-92MI cells in PBS were intravenously
injected in four doses (one initial dose of 1 × 106 cells, followed by four booster doses of
0.5 × 106 cells) with three- or four-day intervals. Untreated control mice were injected
with equal volumes of PBS simultaneously. The length and width of the tumors were
measured with an electronic caliper, and tumor volume was estimated using the
following formula: tumor volume = 1/2(length × width2) (Tomayko and Reynolds, 1989).
2.4: Histology and immunohistochemistry
At the endpoints of animal experiments, tumors were harvested and fixed in 10%
phosphate-buffered formalin. Samples were embedded in paraffin and sliced into
sections at the Histotechnology Facility at the Wistar Institute. Slides were stained with
H&E stain by staff at the facility.
To assess mTORC1 activity and apoptosis in tumor samples, IHC for phosphoS6 ribosomal protein (pS6) and cleaved caspase-3 was performed, respectively. Briefly,
slides with tissue sections in paraffin were deparaffinized and treated with Dako Target
Retrieval Solution, pH 9 (Agilent, S236784-2), following the manufacturer's protocol.
Rabbit anti-pS6 (Ser235/Ser236) primary antibody (Cell Signaling Technology, 2211,
1:400) or rabbit anti-cleaved caspase-3 (Asp175) antibody (Cell Signaling Technology,
9661, 1:400) was applied, followed by HRP-conjugated secondary antibody. A solution
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containing the chromogen DAB was used to detect the primary antibodies, followed by
subsequent hematoxylin counterstain.
The specificity of the antibodies used in the immunohistochemistry experiments
was confirmed at the Histotechnology Facility using tissue samples with known presence
or absence of the targets.
2.5: Flow cytometry
To study the effect of Torin 1 or pHe on mTORC1 activity in NK-92 cells, cells
were treated with Torin 1 or pH-controlled culture media for four hours before being fixed
with 4% paraformaldehyde (PFA) in PBS for 20 min at room temperature. Cells were
washed with PBS before permeabilization using Intracellular Staining Permeabilization
Wash Buffer (BioLegend, 421002) according to the manufacturer's directions. Cells were
then stained with PE-Cy7-conjugated rabbit anti-pS6 (Ser235/Ser236) antibody (Cell
Signaling Technology, 34411) or isotype control antibody (Cell Signaling Technology,
97492) at 1:50 dilution for 20 min on ice before analysis.
To assess the effect of trametinib or target cell engagement on ERK activity in
NK-92 cells, cells were treated with trametinib for one hour or incubated with K562 cells
at 1:1 ratio for zero to two hours before being fixed with 4% PFA in PBS for 20 min at
room temperature. Cells were then permeabilized with ice-cold methanol for 20 min with
constant, gentle agitation, washed with PBS, and stained with PE-Cy7-conjugated rabbit
anti-phospho-p44/42 MAPK (pERK1/2) (Thr202/Tyr204) antibody (Cell Signaling
Technology, 98168) or appropriate isotype control antibody (Cell Signaling Technology,
97492) at 1:50 dilution for 30 min on ice before analysis.
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To assess the basal levels of granzyme B or perforin in NK-92 cells, untreated
cells were fixed, permeabilized, and stained following the same procedures for pS6
staining. For granzyme B, cells were stained with PerCP-Cy5.5-conjugated mouse antigranzyme B antibody (BioLegend, 372211) or isotype control antibody (BioLegend,
400149) at 1:50 dilution. For perforin, cells were stained with PE-Dazzle 594-conjugated
mouse anti-human perforin antibody (BioLegend, 308131) or corresponding isotype
control antibody (BioLegend, 400357) at 1:50 dilution. All staining procedures were
performed on ice for 20 min.
All flow cytometry experiments were performed using Guava easyCyte flow
cytometer (Millipore), and the resulting data were analyzed using FlowJo (FlowJo, LLC)
software. Gates for positive events were set appropriately using untreated and isotype
controls as references. No compensation was applied when analyzing the flow cytometry
data.
2.6: In vitro cytotoxicity and conjugation assay
In vitro cytotoxicity assays were performed using flow cytometry, following a
previously reported method with modifications (Kim et al., 2007). Briefly, human
melanoma cells were adjusted to a concentration of 106 cells/ml and were loaded with
CellTrace Yellow (Invitrogen, C34567), a fluorescent cell-labeling dye, at 1:500 dilution
for 20 min at 37°C. Then, cells were washed with complete culture media to remove
excess dyes before being seeded at 5 × 104 cells/well in 24-well plates one day ahead of
the cytotoxicity assay.
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To study the effect of pH on in vitro cytotoxicity of NK-92 cells, cells were
preincubated in pH-controlled culture media for 24 hours. To study the effect of
pharmacological mTORC1 or ERK inhibition, cells were pretreated with Torin 1 for four
hours or trametinib for one hour, respectively. After incubation, NK-92 cells were
counted and added at 3:1 ratio to WM3629 cells seeded as previously described. After
six-hour incubation, cells were dissociated from culture plates using Accumax cell
dissociation solution (Sigma, A7089) and analyzed using Guava easyCyte flow
cytometer. The total number of surviving melanoma cells were calculated using the
volume of cell mixture, concentration of events, and the percentage of CellTrace Yellowpositive events in all events. Percent survival was calculated by dividing the number of
surviving melanoma cells in NK-92-containing wells by the number of surviving
melanoma cells in control wells (without NK-92 cells), and percent killing was calculated
by 100% − percent survival.
Conjugation assay was performed using flow cytometry as previously described
(Burshtyn and Davidson, 2010). K562 cells as targets were loaded with CellTrace Yellow
dye following a similar labeling procedure as described for the cytotoxicity assay. NK-92
cells, which express EGFP from the transduced lentiviral vectors, were mixed with
labeled K562 cells at 1:2 ratio for 0 to 60 min. At the end of each time point, cells were
fixed with 2% PFA for 20 min at 37°C followed by flow analysis. Percent conjugation was
calculated by dividing the number CellTrace Yellow-EGFP double-positive events by the
number of all EGFP-positive events.
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2.7: Western blot
NK-92 cells were incubated in pH-controlled culture media for six or 24 hours.
Media were removed by centrifugation, and cells were quickly washed with PBS
adjusted to the same pH as culture media to minimize the effect of washing on pHi. Total
protein from cells was harvested by passive lysis with M-PER Mammalian Protein
Extraction Reagent (Thermo Scientific) supplemented with Protease Inhibitor Cocktail
(Promega, G6521), Phosphatase Inhibitor Cocktail 2 and 3 (Sigma, P5726 and P0044).
Protein lysates were cleared by centrifugation, quantified using DC Protein Assay (BioRad, 5000111), and resolved by SDS-PAGE gels. Protein from gels was transferred
onto nitrocellulose membranes using iBlot 2 Dry Blotting System (Invitrogen).
Membranes were blocked using Intercept (TBS) Blocking Buffer (LI-COR, 927-60001)
before incubation with the following primary antibodies: rabbit anti-RHEB (Cell Signaling
Technology, 13879S, 1:1000), rabbit anti-phospho-p70 S6 kinase (pS6K) (Thr389) (Cell
Signaling Technology, 9205S, 1:1000), rabbit anti-S6K (Cell Signaling Technology,
9204S, 1:1000), rabbit anti-pS6 (Ser235/236) (Cell Signaling Technology, 4858S,
1:2000), mouse anti-S6 (Cell Signaling Technology, 2317S, 1:1000), mouse anti-αtubulin (Sigma, CP06, 1:8000), mouse anti-NHE1 (Santa Cruz Biotechnology, sc136239, 1:500), rabbit anti-pERK1/2 (Thr202/Tyr204) (Cell Signaling Technology,
4370S, 1:2000), rabbit anti-ERK1/2 (Cell Signaling Technology, 4695S, 1:1000), rabbit
anti-CA9 (Novus Biologicals, NB100-417, 1:2000), mouse anti-perforin 1 (Santa Cruz
Biotechnology, sc-374346, 1:300), and rabbit anti-granzyme B (Cell Signaling
Technology, 4275S, 1:2000). Secondary antibodies included Alexa Fluor 680-conjugated
goat anti-rabbit IgG (H+L) (Invitrogen, A-21109, 1:8000) and DyLight 800-conjugated
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goat anti-mouse IgG (Cell Signaling Technology, 5257S, 1:15000). All antibodies were
diluted in 5% BSA in TBS supplemented with 0.1% Tween 20 (TBS-T). Immunoblots
were imaged with Odyssey CLx Imaging System (LI-COR). Images were processed with
Image Studio software (LI-COR) with linear contrast enhancement.
2.8: Degranulation assay
Degranulation assay was performed based on a previously reported protocol
(Lorenzo-Herrero et al., 2019, p. 10) with modifications. The method quantifies cell
surface CD107a (LAMP1) without permeabilizing the cells. CD107a is a lysosomal
marker present on the surface of lytic granules that only reaches the plasma membrane
during degranulation. Briefly, 2.5 × 104 NK-92 cells and 5 × 104 K562 cells in 100 µl of
culture media were seeded into 96-well U-bottom plates. If the effect of pH was to be
examined, cells were preincubated in pH-controlled culture media for 24 hours prior to
seeding. PE-Cy7-conjugated mouse anti-human CD107a antibody (BD Biosciences,
561348) or isotype control antibody (BD Biosciences, 557872) was added at 5 ul/well.
After one-hour incubation, GolgiStop (containing monensin) (BD Biosciences, 554724)
and GolgiPlug (containing brefeldin A) (BD Biosciences, 555029) were added at 4 µl/6
ml and 6 µl/6 ml, respectively, to inhibit the internalization of cell surface CD107a due to
trafficking. Cells were analyzed using a flow cytometer for PE-Cy7 fluorescence after a
total of six hours of incubation.
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2.9: pHi and NHE1 activity
pHi of NK-92 cells was measured by staining with SNARF-1, a ratiometric pH
indicator dye, based on a similar method reported previously (Wieder et al., 1993).
Briefly, NK-92 cells were loaded with 5 µM of 5-(and-6)-carboxy SNARF-1,
acetoxymethyl ester, acetate (Invitrogen, C1272) in PBS for 20 min at 37°C. The dye is
cell-permeant due to its ester modification but is retained in cells once absorbed
because of hydrolysis of the ester group catalyzed by intracellular esterases. Excessive
dyes were removed by washing the cells with serum-containing culture media
(containing esterases), and cells were allowed to recover in media for 30 min at 37°C.
The media were then changed to either pH-controlled live-cell imaging buffers (140 mM
NaCl, 2.5 mM KCl, 1.8 mM MgCl2, 1 mM CaCl2, 5 mM D-glucose, 10 mM HEPES, and
10 mM PIPES) or pH-controlled high-potassium (K+) buffers from the Intracellular pH
Calibration Buffer Kit (Invitrogen, P35379), and cells were allowed to accommodate for
30 min at room temperature and atmospheric CO2. Cells in high-potassium buffers were
further treated with 10 µM of H+/K+-ionophores nigericin and valinomycin to equilibrate
pHe and pHi. Finally, cells were analyzed using a flow cytometer with dual fluorescent
emissions measured at around 580 and 640 nm wavelengths. The ratio of emission at
these two wavelengths correlates with pH. This ratio for cells in the high-potassium
buffers was plotted against the pH of the buffers, and second-order polynomial fit was
used to derive a standard curve for interpolation to determine the baseline pHi of the
cells in the pH-controlled live-cell imaging buffers.
NHE1 activity was measured as the rate of pHi recovery after an acute acid load
caused by ammonium chloride (NH4Cl), as previously described (Dong et al., 2021). NK38

92 cells were first loaded with SNARF-1 following the same procedure as in the
measurement of pHi. Then, a portion of cells was used to generate a standard curve
using high-potassium buffers as previously described. The remaining cells were first
incubated in an isotonic NH4Cl solution (50 mM NH4Cl, 70 mM choline chloride, 5 mM
KCl, 1 mM MgCl2, 2 mM CaCl2, 5 mM glucose, and 20 mM HEPES-Tris, pH 7.4) for 5 min
at room temperature and atmospheric CO2. Next, an acute acid load was induced by
incubating the cells with an isotonic Na+-free solution (125 mM choline chloride, 1 mM
MgCl2, 2 mM CaCl2, 5 mM glucose, and 20 mM HEPES-Tris, pH 7.4) for 10 min.
Following the incubation, the solution was replaced by a Na+-rich recovery solution
(140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 10 mM glucose, and 10 mM
HEPES, pH 7.4), and cells were immediately analyzed on a flow cytometer for dual
fluorescent emission as in the measurement of pHi. pHi was measured in the first ten
minutes of recovery, and the rate of pHi recovery was calculated using linear regression
based on the data between two and five minutes, which showed the highest linearity. A
high pHi recovery rate indicates high NHE1 activity.
2.10: QuantSeq 3' mRNA-sequencing
Library preparation and sequencing experiments were performed by staff at the
Genomics Facility at the Wistar Institute. Libraries for 3' mRNA-sequencing were
generated from 100 ng of DNase I-treated total RNA using QuantSeq 3' mRNA-Seq
Library Prep Kit FWD (Lexogen), according to the manufacturer's directions. Overall
library size was determined using the Agilent TapeStation and the D5000 ScreenTape
System (Agilent). Libraries were quantified using real-time PCR with kits from Kapa
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Biosystems. Finally, libraries were pooled for high-output, single-read, 75-base-pair nextgeneration sequencing on a NextSeq 500 sequencer (Illumina).
The quality of the sequencing reads was checked using FastQC. Read mapping
was performed using Kallisto, a pseudoalignment program enabling lightweight yet
accurate RNA-seq quantification (Bray et al., 2016). Downstream analyses were all
performed using R (version 4.1.2) with indicated packages. First, differentially expressed
genes were identified using Limma-Voom. Then, a heatmap of differentially expressed
genes was generated with gplots. Next, we used clusterProfiler to determine the
enrichment of transcription binding sites curated in category C3 of the MSigDB
database. Finally, we used GSEABase to perform gene set enrichment analysis (GSEA)
and plotted the results using enrichplot.
2.11: Visualization of immunological synapses
Immunological synapses are the interface formed between immune effector cells
and their target cells (Orange, 2008). Dr. Yu Li in the Orange Lab at Columbia University
performed the microscopy experiments visualizing the immunological synapses of
antibody-activated NK-92 cells.
To characterize immunological synapses formed by NK-92 cells, thoroughly
cleaned glass coverslips were coated with 5 µg/ml of purified anti-human CD18
(BioLegend, 302102) and purified anti-human CD337 (NKp30) antibodies for 30 min at
37°C. CD18 is an integrin involved in NK cell adhesion, and CD337 is an activating NK
receptor recognizing target cells. Excess antibodies were removed with PBS washes,
and the coverslips were transferred to a six-well plate. NK-92 cells were added onto the
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coverslips at a concentration of 2 × 105 cells/ml in complete culture media and were
allowed to adhere and form immunological synapses for 30 min at 37°C. Coverslips with
cells were washed with PBS before being treated with 2% PFA for fixation. Fixed cells
were permeabilized with 0.1% Triton X-100, blocked with 5% BSA, and stained with
DAPI, Alexa Fluor 568-conjugated phalloidin (Invitrogen, A12380, 1:100), and Alexa
Fluor 647-conjugated anti-human perforin antibody (BioLegend, 308110, 1:100) for one
hour. Coverslips were mounted onto glass slides, and stained cells were visualized
under a confocal microscope with optical sectioning at 0.25 µm increments from the cellsurface contact site.
We assessed the convergence of perforin-containing lytic granules around the
immunological synapses as previously reported (Hsu et al., 2017a; Mukherjee et al.,
2017). Higher convergence of lytic granules is correlated with increased cytotoxicity of
NK cells. Briefly, we measured the average distance between individual lytic granules
and the geometric center (centroid) of all the granules in each cell using a max
projection image of the Z-stack images obtained by confocal microscopy. The distance
serves as a measurement of the spread of lytic granules in the X-Y direction, as a higher
average distance indicates more spread (and less convergence). To assess the spread
of lytic granules along the Z-axis, we measured the size of the perforin-positive area on
each slice of the Z-stack using the automatic thresholding method Maximum Entropy in
the ImageJ software and plotted the normalized area against distance based on slice
number. Then, assuming Gaussian distribution of lytic granules along the Z-axis, we
performed Gaussian fit to derive the standard deviation of the perforin-positive area.
Alternatively, we calculated the percentage of lytic granules within the first 4 µm above
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the cell-surface contact plane (first 16 slices) as a separate measurement of lytic granule
convergence at the vertical direction relative to the cell-surface contact plane.
2.12: Seahorse metabolic flux assay
To characterize the metabolic profile of human melanoma cell lines, Ms. Patricia
Brafford performed the Seahorse metabolic flux assay using the Seahorse XFe96/XF
Pro FluxPak (103792-100, Agilent) according to the manufacturer's instructions. Briefly,
human melanoma cell lines were seeded at 2 × 104 cells/ml in XF96 cell culture
microplates included in the kit, with 80 µl per well. Cells were allowed to attach
overnight. The culture media were replaced on the next day with 180 µl of Seahorse
assay media (pH 7.4) prewarmed to 37°C. Measurements of oxygen consumption rate
(OCR) and extracellular acidification rate (ECAR) were performed on an XFe96 analyzer
(Agilent) after equilibrating the cells in the assay medium for one hour. The Seahorse
analyzer uses optical fluorescent O2 and pH sensors embedded in a sterile disposable
cartridge, one for each well. Before each rate measurement, the plungers mix assay
media in each well to allow the oxygen partial pressure to reach equilibrium. The
plungers gently descend into the wells to measure rates, forming a chamber that entraps
the cells. O2 concentration and pH are periodically measured over a short duration, and
OCR and ECAR are obtained from the slopes of concentration change in these
parameters versus time. After the rate measurements, the plungers ascend, and the
plate is gently agitated to re-equilibrate the medium. OCR is reported in the unit of
picomoles per minute (pMol/min), and ECAR is reported in milli-pH units per minute
(mpH/min). Baseline rates are measured four times. One or more testing chemicals are
preloaded in the reagent delivery chambers of the sensor cartridge and then
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pneumatically injected into the wells to reach the desired final working concentration.
After 2 min of mixing, postexposure OCR and ECAR measurements are made four to six
times. The averages of the baseline are reported.
2.13: Statistics
All data with replicates are expressed as mean ± SEM. Unpaired, two-tailed
Student's t-test was performed for comparisons involving two groups. One-way or twoway ANOVA followed by Dunnett's multiple comparisons test was performed for
comparisons involving more than two groups. Linear regression was performed to
determine the pHi recovery rate. Second-order polynomial fit was performed to derive
the calibration curve in the measurement of pHi. Spline fit was performed to obtain an
approximation of the pHe-pHi curve. Gaussian fit was performed to assess the spread of
perforin-containing granules, with F-test to compare the variances across the groups. A
p-value of less than 0.05 was considered statistically significant. Pairwise comparisons
are not statistically significant unless marked with asterisks. All statistical analyses were
performed using GraphPad Prism 9 (GraphPad Software).
2.14: Study approval
All animal experiments were approved by the IACUC at the Wistar Institute
(protocol numbers 201189 and 201379) and performed following the guidelines of
IACUC and NIH.
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CHAPTER 3: Results
3.1: Systemic buffering negated the effect of anti-PD1 antibody in a mouse HCC model
Multiple studies have shown that acidic culture media inhibit the antitumor activity
of immune effector cells such as cytotoxic T cells (Bosticardo et al., 2001; Brand et al.,
2016; Calcinotto et al., 2012; Fischer et al., 2007; Haas et al., 2015; Mendler et al.,
2012, p. 38; Nakagawa et al., 2015; Pilon-Thomas et al., 2016; Wu et al., 2020).
Therefore, it is hypothesized that the acidic TME of solid tumors may suppress the
antitumor activity of infiltrating immune cells. To target tumor acidity, others have
devised the strategy of systemic buffering, where tumor-bearing animals were fed orally
with NaHCO3 to neutralize tumor acidity (Robey et al., 2009). This method was
previously found to synergize with immunotherapies such as ICB using anti-PD1
antibody and the adoptive transfer of T cells in a melanoma mouse model (PilonThomas et al., 2016). In this regard, we hypothesized that systemic buffering with oral
NaHCO3 would enhance T cell or NK cell function and would thus synergize with antiPD1 in treating transgenic mice with c-Myc-induced HCC (Xiang et al., 2015).
In this Tet-Off inducible c-Myc model, silencing of c-Myc expression is achieved
by the treatment with doxycycline (DOX, Figure 4A), which prevents HCC tumor
formation. After removing DOX to initiate HCC tumorigenesis, we treated the mice with
or without NaHCO3 and an anti-PD1 antibody and assessed the effect of the treatments
on tumor formation using liver weight as a surrogate for tumor weight. Unexpectedly,
contrary to others' observation that systemic buffering by NaHCO3 synergized with antiPD1 in a tumor model (Pilon-Thomas et al., 2016), we found that systemic buffering by
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NaHCO3 negated the antitumor effect of anti-PD1 antibody (Figure 4A) in our model.
Further, the accelerated tumor growth in NaHCO3-treated mice was concomitant with a
remarkable increase in tumor cell mTORC1 activity (Figure 4B and C), which we
observed previously in mice with xenografts of the HCT116 human colon or MCF7
breast cancer cell lines (Walton et al., 2018). mTORC1 is thought to be a driver of
murine HCC, as sustained activation of mTORC1 is sufficient to cause murine HCC
(Menon et al., 2012). Therefore, a possible explanation for the accelerated tumor growth
in NaHCO3-treated mice is that systemic buffering activated the mTORC1 in tumor cells,
promoting HCC tumorigenesis.
In this instance, systemic bicarbonate administration had adverse effects,
indicating that treatment response depends on specific tumor models and the
dependency of tumor cells on mTORC1 activity for tumor growth. Therefore, we focused
on metabolically engineering immune effector cells for ACT as an alternative approach
to target the adverse effect of acidity within the TME.
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Figure 4. Systemic buffering negated the effect of anti-PD1 antibody in a mouse
hepatocellular carcinoma (HCC) model.
(A) Liver weight of mice with doxycyclin (DOX)-repressible c-Myc-driven HCC fed with
regular or sodium bicarbonate (NaHCO3)-containing drinking water and treated with
anti-PD1 antibody (iPD1) or isotype control (IgG) (N = 10, 43, 43, 30, and 31 for H2O +
DOX, H2O + IgG, NaHCO3 + IgG, H2O + iPD1, and NaHCO3 + iPD1 groups,
respectively; unpaired t-test). (B) Representative microscopic images of the mTORC1
target phospho-S6 ribosomal protein (pS6)-stained tumor slices. Scale: 100 μm (inset:
40 μm). (C) Quantification of pS6-positive objects in images in B (N = 5 whole-tumor
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scans from different animals, one-way ANOVA with multiple comparisons). * p < 0.05,
*** p < 0.001.
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3.2: NK-92 cells as model immune effector cells for metabolic engineering
To study the metabolic engineering of immune effector cells, we sought an
experimentally tractable system amenable to genetic manipulations. Unfortunately,
primary immune effector cells such as CD8+ T cells and NK cells are difficult to
manipulate, expand, and select after genetic manipulation; hence experimentally less
tractable for our proof-of-concept study of metabolic engineering (Klingemann et al.,
2016). Therefore, we used the human NK cell line NK-92 isolated from a non-Hodgkin
lymphoma patient (Gong et al., 1994). NK-92 cells resemble activated NK cells and
express many activating NK receptors, including NKp30, NKp44, NKp46, and NKG2D,
but lack most of the inhibitory receptors except for low levels of KIR2DL4 (Maki et al.,
2001). The lack of inhibitory receptors may contribute to the superior cytotoxicity of NK92 against a range of hematological and solid tumor cells (Fabian and Hodge, 2021). As
an attractive off-the-shelf product for allogenic ACT, irradiated NK-92 cells have been
tested in several Phase I clinical trials for patients with solid tumors, including renal cell
carcinoma and lung cancer (Arai et al., 2008; Tonn et al., 2013). There is also an
ongoing effort to express CARs in NK-92 cells to improve the availability and affordability
of immunotherapies. For example, studies have generated engineered NK-92 cells
expressing CARs targeting tumor antigens such as ErbB2 (HER2), which is
overexpressed in certain breast cancers and glioblastomas (Zhang et al., 2016), and
GD2, which is frequently overexpressed in solid tumors like neuroblastoma (Mitwasi et
al., 2020). However, the limited clinical response to date underscores the need for
developing modified NK-92 cells with enhanced antitumor activity. In particular, we
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hypothesize that tumor acidity is a major factor blunting cytotoxic immune cells and that
metabolic engineering could mitigate the inhibitory effect of acidity.
To develop a tumor model for engineered NK-92 cells, we first tested the in vitro
cytotoxicity of unmodified NK-92 cells against a panel of previously characterized human
melanoma cell lines that the Herlyn Lab at the Wistar Institute provides (Li et al., 2017).
As the survival, proliferation, and cytotoxicity of NK-92 cells depend on the activating
cytokine IL-2 (Gong et al., 1994), we added IL-2 to the culture media of NK-92 cells
throughout the assays described in this work. We observed varying degrees of
cytotoxicity depending on the target melanoma cell line (Figure 5A). Among the human
melanoma cell lines tested, we focused on WM3629, an NK-92-sensitive cell line that
forms aggressive tumor xenografts in immunodeficient mice (Smalley et al., 2009).
To understand the different sensitivity of the human melanoma cell lines to NK92 cells, we assessed the expression levels of known NK receptor ligands by QuantSeq
3' mRNA-sequencing and probed the metabolic activity of the cell lines by Seahorse
metabolic flux assay (measuring basal oxygen consumption rate (OCR) and extracellular
acidification rate (ECAR)) (Table 2). We hypothesized that increased expression of
activating NK receptor ligands or decreased inhibitory NK receptor ligands underlies
sensitivity to NK-92 cells. Alternatively, as a research interest in the Dang Lab, we
hypothesized that the different metabolic profile of the melanoma cell lines might
determine their sensitivity to NK-92 cells. Therefore, we calculated Spearman's rankorder correlation between the sensitivity of the melanoma cell lines to NK-92 cells and
the expression levels of known NK receptor ligands or the oxidative and glycolytic
metabolic activities of the melanoma cell lines. Unfortunately, none of the factors
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assessed was significantly correlated with the sensitivity of these cells to NK-92 cells.
There are several possibilities for the lack of correlation. First, the inclusion of only five
human melanoma cell lines is not enough to derive meaningful correlational statistics.
Second, although we included multiple characterized NK receptor ligands, NK receptors
with uncharacterized ligands might influence the sensitivity of the melanoma cells to NK92 cells. Third, the sensitivity of the melanoma cell lines might depend on the balance
among multiple factors, including the expression of activating or inhibitory NK receptor
ligands and metabolic activity of the cells, which could not be determined by simple
correlational studies.
Like cytotoxic T cells, the effector function of NK-92 cells depends on immune
synapse formation and the subsequent release of cytolytic proteins such as granzyme B
(Suck et al., 2016). As such, we validated our cytotoxicity assay and documented that
overexpressing SERPINB9, a natural inhibitor of granzyme B, in melanoma target cells
rendered them resistant to NK-92 cytotoxicity (Figure 5B). The ability of overexpressed
SERPINB9 to confer resistance to NK-92 cytotoxicity validated our in vitro cytotoxicity
assay. Moreover, as has been reported for primary NK cells, we found that NK-92 cells
also exhibited diminished cytotoxicity in acidic culture media (Figure 5C). These
features of NK-92 cells make them an attractive and tractable ACT model for our study.
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Figure 5. NK-92 cells show cytotoxicity against several human melanoma cell
lines in vitro.
(A) In vitro cytotoxicity of NK-92 cells against human melanoma cell lines WM3629,
WM3854, WM4231, WM4237, and WM852 at various effector-to-target (E-T) ratios (N
= 3 wells for each condition). (B) In vitro cytotoxicity of NK-92 cells against WM3629
cells overexpressing SERPINB9, a granzyme B inhibitor, at various E-T ratios (N = 3
wells, unpaired t-test). (C) In vitro cytotoxicity of NK-92 cells against WM3629 cells in
pH-controlled media (defining extracellular pH, or pHe) (N = 4 wells). *** p < 0.001.
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Table 2. Correlation between the sensitivity of the five human melanoma cell lines
to NK-92 killing and their expression of NK receptor ligands or metabolic.
Expression levels of NK receptor ligands were measured by QuantSeq 3' mRNAsequencing, and the normalized counts are shown. None of the cell lines express the
known NKG2D ligand RAET1L/ULBP6. Total HLA-A, B, and C in the cell lines was
assessed by flow cytometry and normalized to that in WM4265 cells. Metabolic profiles
of the cell lines were assessed by Seahorse assay, with the basal oxygen consumption
rate (OCR, in pMol/min) and extracellular acidification rate (ECAR, in mpH/min).
Spearman's rank-order correlation was calculated between the average percent killing of
the melanoma cell lines by NK-92 cells in experiment 1 and other measurements.
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WM4237

WM3629

WM4231

WM3854

WM852

p-value for
Spearman
correlation
with %
killing

47.25

32.87

19.45

9.18

6.70

0.0167

Yes

52.65

37.2

16.62

10.93

7.75

0.0167

Yes

MICA

911.12

948.35

56.49

455.66

573.74

0.45

No

MICB

270.82

242.66

208.18

322.88

692.76

0.35

No

ULBP1

43.94

16.74

3.14

57.33

40.91

0.95

No

ULBP2

16.14

58.57

0.00

79.46

31.62

0.6833

No

ULBP3

2.69

0.00

0.00

3.02

0.00

>0.9999

No

0.00

6.51

0.00

6.04

48.35

0.3

No

0.00

4.65

6.28

5.03

18.60

0.0833

No

77.12

154.34

223.87

48.28

50.21

0.45

No

2010.56

1554.54

2324.52

1409.21

1725.86

0.6833

No

1884.11

3546.07

1727.18

3141.31

3888.77

0.45

No

10766.63

4350.30

4379.14

2985.40

7599.92

0.6833

No

17.04

0.93

0.00

11106.73

2.79

0.95

No

0.79

0.98

0

0.09

1.8

0.7833

No

65.00

87.77

89.23

229.81

32.88

>0.9999

No

44.54

53.30

26.49

96.63

15.73

0.6833

No

Cell line
Average % killing at E:T =
0.5:1 (experiment 1)
Average % killing at E:T =
0.5:1 (experiment 2)

NKG2D
ligands
QuantSeq
(activating)

RAET1E/
ULBP4
RAET1G
/ULBP5
NCR3LG
1/B7-H6

NKp30
ligands
QuantSeq
BAG6
(activating)
NKp44 ligand
QuantSeq
PCNA
(activating)
NKG2C
HLA-E
ligand
QuantSeq
HLA-G
(inhibitory)
Relative intensity of total
HLA-A, B, and C by flow
(potentially inhibitory)
Basal
OCR
Metabolic
profile
Basal
ECAR
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Significant
correlation
(p < 0.05)

3.3: Activating mTORC1 by RHEB enhances the cytolytic activity of NK-92 cells
As a proof of concept for metabolic engineering, we first sought to restore
signaling pathways in immune cells affected by acidosis, such as mTORC1, as we
reported previously that acidic culture media blunts mTORC1 activity in CD8+ T cells
(Walton et al., 2018). We showed that the acidic environment promotes the anterograde
trafficking of lysosomes away from the MTOC and towards the cell periphery in epithelial
cells, which separates lysosomal mTORC1 and perinuclear RHEB, a necessary protein
for mTORC1 activation. If the same observation holds in NK-92 cells, in addition to
inhibiting mTORC1 activity, acidity could also cause polarization of granzyme B- and
perforin-containing lytic granules away from the MTOC (Figure 1) and the immunologic
synapse, thereby diminishing degranulation and cytotoxicity.
mTORC1 activity is crucial for the effector function of NK cells, as mTORC1
metabolically primes NK cells for effector function (Donnelly et al., 2014), and deletion of
the mTORC1 component Raptor impairs the effector function of mouse NK cells (Wang
et al., 2018). In addition, we also observed that pretreating NK-92 cells with Torin 1, a
selective mTOR inhibitor, reduced their in vitro cytotoxicity in a dose-dependent manner
(Figure 6A). Therefore, we tested whether we could restore the cytolytic activity of NK92 cells in an acidic environment by boosting mTORC1 activity. We overexpressed a
constitutively active RHEB that constantly activated mTORC1 (RHEBN153T, hereafter
referred to as RHEB) (Urano et al., 2005) in NK-92 cells and observed elevated
mTORC1 signaling, as indicated by the increased phosphorylation levels of mTORC1
substrates p70 S6 kinase (pS6K) and S6 ribosomal protein (pS6), in the resulting cells at
neutral or increasingly acidic pHs (Figure 6B). Further, RHEB-overexpressing cells
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demonstrated enhanced in vitro cytotoxicity (Figure 6C) and degranulation (Figure 6D)
towards tumor cells over the pHe range of 6.6 to 7.4, suggesting increased cytolytic
activity. These observations are consistent with the previous report that overexpressing
a wild-type RHEB in primary human CD8+ T cells enhanced their cytolytic activity (Veliça
et al., 2015). However, as documented, sustained mTORC1 activity in CD8+ T cells
rendered them incapable of transitioning into a memory state, potentially limiting their
long-term efficacy (Pollizzi et al., 2015). Hence, we sought an orthogonal approach to
metabolically engineer immune effector cells with proton extruders using NK-92 cells in a
proof-of-concept study.

55

Figure 6. Activating mTORC1 by RHEB enhances cytolytic activity of NK-92
cells.
(A) In vitro cytotoxicity of Torin1 (mTOR inhibitor)-treated NK-92 cells against the
human melanoma cell line WM3629, relative to the untreated cells (N = 6 wells, X-axis
in log2 scale). (B) Representative immunoblots of the mTORC1 phosphorylation
substrates phospho-p70 S6 kinase (pS6K) and phospho-S6 ribosomal protein (pS6) in
constitutively active RHEB (RHEBN153T, hereafter referred to as RHEB)-overexpressing
or empty vector (EV) control NK-92 cells treated with pH-controlled media (defining
extracellular pH, or pHe) for 6 or 24 hours. (C) In vitro cytotoxicity of RHEB-expressing
or EV control NK-92 cells against human melanoma cell lines WM3629 and WM4237
in pH-controlled media (N = 4 wells for each cell line in two independent experiments,
unpaired t-test). (D) Degranulation of RHEB-overexpressing or EV control NK-92 cells

56

towards the human leukemia cell line K562 in pH-controlled media (N = 3 wells,
unpaired t-test). * p < 0.05, ** p < 0.01, *** p < 0.001.
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3.4: CA9 does not rescue the acid-blunted cytolytic activity of NK-92 cells
Since restoring the acid-blunted mTORC1 could enhance the cytotoxicity of
immune cells, we next determined whether direct metabolic engineering of immune cells
by overexpressing acid extruder proteins could rescue their acid-blunted mTORC1
activity and thereby enhance in vitro cytotoxicity. We first overexpressed CA9 in NK-92
cells. CA9 is a hypoxia-inducible, membrane-bound extracellular carbonic anhydrase
catalyzing the reversible hydration of CO2, a cell-permeant acid equivalent, at the cell
surface and is thought to promote tumor growth by protecting tumor cells from acidosis
(Chiche et al., 2008). The current model for CA9-mediated intracellular alkalinization
involves the neutralization of intracellular acid by bicarbonate ions catalyzed by the
intracellular carbonic anhydrase II (CA2), the diffusion of the resulting CO2 to the
extracellular space, the hydration of the CO2 at the extracellular space by CA9, and the
recycling of bicarbonate ions via bicarbonate channel proteins such as NBCe1 (Figure
7) (Ditte et al., 2011). Therefore, we hypothesized that CA9 would enhance the cytolytic
activity of NK-92 cells by increasing their pHi and mTORC1 activity.
However, overexpressed CA9 failed to elevate baseline pHi (Figure 8A) of NK92 cells, although it partially rescued the acid-blunted mTORC1 activity (Figure 8B). The
elevation of mTORC1 activity by CA9 in the absence of a measurable increase in pHi
was unexpected, and we have not determined the mechanism of how ectopic CA9
activates mTORC1. Importantly, ectopic CA9 could not consistently enhance NK-92
cytotoxicity (Figure 8C) or degranulation (Figure 8D) towards tumor target cells, despite
the elevation of mTORC1. The failure of CA9 alone to increase pHi could be because
CA9 may require additional proteins, including the intracellular carbonic anhydrase CA2
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and sodium bicarbonate cotransporter 1 (NBCe1), to efficiently alkalinize the cytoplasm
according to the previously proposed model (Ditte et al., 2011). Intriguingly, the lack of
sufficient cytoplasmic alkalinization or cytotoxicity by CA9 overexpression was
accompanied by increased mTORC1 activity, suggesting that the partially rescued
mTORC1 under low pHe was insufficient for enhanced NK-92 cytolytic activity. As such,
whether the constitutively active RHEB, which enhanced mTORC1 activity, has an
additional function (Karbowniczek et al., 2004) in increasing NK-92 cytotoxicity remains
to be established.
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Figure 7. Schematic representation of carbonic anhydrase IX (CA9).
CA9 is a hypoxia-inducible, membrane-bound extracellular carbonic anhydrase
catalyzing the reversible hydration of carbon dioxide (CO2), a cell-permeant acid
equivalent, at the cell surface. The current model for CA9-mediated intracellular
alkalinization involves the neutralization of intracellular acid by bicarbonate ions
catalyzed by the intracellular carbonic anhydrase II (CA2), the diffusion of the resulting
CO2 to the extracellular space, the hydration of the CO2 at the extracellular space by
CA9, and the recycling of bicarbonate ions via bicarbonate channel proteins such as
NBCe1. The net effect of CA9 is intracellular alkalinization and extracellular
acidification.
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Figure 8. CA9 fails to enhance the antitumor activity of NK-92 cells in vitro.
(A) Baseline intracellular pH (pHi) of NK-92 cells expressing CA9 or empty vector (EV)
control in pH-controlled media (defining extracellular pH, or pHe) (N = 3 wells, two-way
ANOVA). (B) Representative immunoblots of mTORC1 targets phospho-p70 S6
kinase (pS6K) and phospho-S6 ribosomal protein (pS6) in NK-92 cells expressing
CA9 or EV treated with pH-controlled media (defining extracellular pH, or pHe) for 6 or
24 hours. (C) In vitro cytotoxicity of NK-92 cells expressing CA9 or EV against
WM3629 cells in pH-controlled media (N = 4 wells, unpaired t-test). (D) Degranulation
of NK-92 cells expressing CA9 or EV towards K562 cells in pH-controlled media (N =
3 wells, unpaired t-test). ns not significant.
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3.5: NHE1 enhances the cytolytic activity of NK-92 cells
As an alternative to CA9, which failed to enhance cytotoxicity, we used the
Na+/H+-exchanger protein NHE1, encoded by the gene SLC9A1, to engineer NK cells
with the ability to extrude H+. NHE1 utilizes the ubiquitous sodium (Na+) gradient across
the plasma membrane of cells, which can be set by pumps such as the Na+/K+-ATPase,
to export protons (H+) in exchange for Na+ influx (Figure 9). Like CA9, NHE1 is also
activated in tumor cells and is known to maintain pHi and promote tumor growth and
tumor cell migration by acidifying their periphery (Busco et al., 2010). In addition, there
has been an emerging interest in using small-molecule NHE1 inhibitors, such as
amiloride and cariporide, to treat cancers with the assumption that these drugs will
deprive tumor cells of their elevated pHi, making them sensitive to treatments with other
therapeutic agents (Harguindey et al., 2013). Therefore, we hypothesized that NHE1
would enhance the cytolytic activity of NK-92 cells by increasing their pHi, which is also
expected to increase mTORC1 activity.
We synthesized the codon-optimized cDNA of human NHE1 with histidine-toarginine mutations at the pH-sensitive histidine clusters, making the resulting NHE1
constitutively active (hereafter referred to as NHE1) regardless of environmental pH
(Webb et al., 2016). As a control, we generated a mutant NHE1 with E262I mutation that
lacks ion exchanger activity (hereafter referred to as NHE1-E262I) (Fafournoux et al.,
1994). We found that NK-92 cells overexpressing the constitutively active NHE1 showed
faster recovery of pHi from an acute acid load, a standard measurement of NHE1
activity, compared with EV- or inactive NHE1-expressing cells (Figure 10A). This
illustrates that the ectopically expressed, constitutively active NHE1 has ion exchanger
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activity in NK-92 cells. In addition, NK-92 cells expressing NHE1 had a higher baseline
pHi than cells overexpressing the inactive mutant NHE1 or empty vector (EV) (Figure
10B), which is consistent with the previous observation that NHE1 helped tumor cells
maintain an alkaline pHi (Busco et al., 2010). Compared with those expressing EV or
NHE1-E262I, these cells also showed heightened in vitro cytotoxicity against different
melanoma cells (Figure 10C and 11A) and degranulation towards melanoma or K562
cells as measured by CD107a surface expression (Figure 10D and 11B). Notably, the
higher cytotoxicity of NHE1-expressing NK-92 was not due to altered proliferation
(Figure 11C) or survival (Figure 11D). In the six-hour time frame of the cytotoxicity and
degranulation assays, survival is an important factor for consideration. The proliferation
rate in vitro was measured in consideration of the potential ability of NK-92 to function in
vivo, which required a much longer time than the in vitro assays. The inability of the
inactive NHE1 to increase cytotoxicity or degranulation suggests that the ion exchanger
activity of NHE1 is required for enhancing the cytolytic activity of NK-92 cells, ruling out
other putative non-catalytic functions of NHE1.
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Figure 9. Schematic representation of Na+/H+-exchanger 1 (NHE1).
NHE1 is an exchanger (antiporter) protein using the Na+ gradient across the plasma
membrane of cells to export H+. The Na+ gradient is ubiquitously present in
mammalian cells, usually set by the pump protein Na+/K+-ATPase. The 12
transmembrane domains of human NHE1 are thought to form the ion exchanger, while
the long cytoplasmic tail is thought to contain binding sites for a variety of regulatory
proteins such as CHP1, ERK, calmodulin, and the ezrin, radixin, and moesin (ERM)
family of actin-binding proteins. The net effect of NHE1 is intracellular alkalinization
and extracellular acidification.
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Figure 10. Overexpressing Na+/H+-exchanger 1 (NHE1) enhances the cytolytic
activity of NK-92 cells
(A) Intracellular pH (pHi) recovery rate of NK-92 cells expressing constitutively active
NHE1 (hereafter referred to as NHE1), inactive NHE1 (hereafter referred to as NHE1E262I), or EV after an acute acid load (N = 3 samples, spline fit, one-way ANOVA with
multiple comparisons). (B) Baseline pHi of NK-92 cells expressing NHE1, NHE1E262I, or EV in pH-controlled media (N = 6 wells, pooled from two independent
experiments, two-way ANOVA with multiple comparisons, smooth connecting curve
generated by second-order polynomial fit). (C) In vitro cytotoxicity of NK-92 cells
expressing NHE1, NHE1-E262I, or EV against the human melanoma cell line
WM3629 in pH-controlled media (N = 6 wells, two-way ANOVA with multiple
comparisons). (D) Degranulation of NK-92 cells expressing NHE1, NHE1-E262I, or EV
towards K562 cells in pH-controlled media (N = 8 wells, pooled from two independent
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experiments, two-way ANOVA with multiple comparisons). * p < 0.05, ** p < 0.01, *** p
< 0.001.
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Figure 11. NHE1 enhances in vitro cytotoxicity of NK-92 cells without affecting
proliferation or survival
(A) In vitro cytotoxicity of NK-92 cells expressing constitutively active NHE1 (referred
to as NHE1) or empty vector (EV) control against human melanoma cell lines
WM1727A and WM4237 in pH-controlled media (defining extracellular pH, or pHe) (N
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= 4, unpaired t-test). (B) Degranulation of NK-92 cells expressing NHE1 or EV towards
K562 cells and WM3629 cells in pH-controlled media (N = 6 wells and pooled from
two independent experiments for K562, N = 4 wells for WM3629, two-way ANOVA
with multiple comparisons). (C) Proliferation of NK-92 cells expressing NHE1, inactive
NHE1 (referred to as NHE1-E262I), or EV over time in pH-controlled media (N = 6,
two-way ANOVA). (D) Survival of NK-92 cells expressing NHE1, NHE1-E262I, or EV
after cytotoxicity with WM3629 human melanoma cells (N = 6, two-way ANOVA with
multiple comparisons). * p < 0.05, ** p < 0.01, *** p < 0.001, ns not significant.
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3.6: The increased cytolytic activity of NHE1-expressing NK-92 cells does not correlate
with the activation of mTORC1 or ERK pathways
We next investigated the mechanisms by which NHE1 enhances the cytolytic
activity of NK-92 cells. We started by assessing the activity of acid-blunted signaling
pathways that can influence NK cell effector functions, such as the mTORC1 pathway.
We have shown that the acidic environment blunts mTORC1 activity (Walton et al.,
2018) and that activating mTORC1 by overexpressing RHEB (Figure 6B) enhances the
cytotoxicity and degranulation of NK-92 cells (Figure 6C and 6D). Therefore, we
hypothesized that NHE1 could rescue acid-blunted mTORC1 activity in NK-92 cells by
elevating pHi, leading to the enhanced cytolytic activity of the cells. Surprisingly, while
NHE1 raised the basal pHi of NK-92 cells, it did not rescue the acid-blunted mTORC1
activity (Figure 12A) as hypothesized. This result, combined with the previous
observation that CA9, while partially rescuing mTORC1 activity, did not enhance the
cytolytic activity of NK-92 cells (Figure 8C and 8D), suggests that elevated mTORC1 is
not necessary for enhanced degranulation or cytotoxicity.
Since NHE1-overexpressing NK-92 cells demonstrated elevated degranulation,
we next assessed the activity of MAPK pathways in the cells, as others have reported
that phosphorylation of ERK is required for the proper orientation of the microtubule
organizing center (MTOC) in NK cells during degranulation (Figure 1) (Chen et al.,
2006, p. 28). In addition, ERK has been shown to physically interact with the ectopically
expressed NHE1 in Chinese hamster ovary (CHO) cells (Hendus-Altenburger et al.,
2016). Congruent with this notion, inhibiting MEK, an upstream kinase of ERK, in NK-92
cells reduced their degranulation (Figure 12B). However, while we observed increased
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basal and target cell-induced ERK phosphorylation in NK-92 cells expressing the
constitutively active NHE1 (Figure 12C, 12D, and 13), the catalytically inactive mutant
NHE1 also increased target cell-induced ERK phosphorylation (Figure 12D) without
enhancing cytotoxicity. These observations indicate that elevated ERK phosphorylation
in NHE1-overexpressing cells is insufficient to induce cytotoxicity. In addition, the
increased ERK phosphorylation as a result of NHE1 overexpression is independent of
NHE1 ion exchanger activity. Instead, it might be due to protein-protein interaction
between NHE1 and ERK at sites outside the ion exchanger domain. For example, ERK
has been shown to phosphorylate NHE1 at multiple sites within the cytoplasmic tail
domain, potentially mediating the interaction (Fliegel, 2019). These results suggest that
ERK phosphorylation is not sufficient to enhance NK-92 cytotoxicity, but it may be
necessary along with other factors to increase degranulation and cytotoxicity. On the
other hand, our results show that altered mTORC1 activity did not correlate with NK-92
degranulation and cytotoxicity, particularly with CA9 overexpression (Figure 8C and
8D), suggesting that under certain conditions increased mTORC1 is not sufficient to
increase degranulation.
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Figure 12. The increased cytolytic activity of NHE1-expressing NK-92 cells does
not correlate with the activation of mTORC1 or ERK pathways
(A) Representative immunoblots from two independent experiments assessing
mTORC1 substrates phospho-p70 S6 kinase (pS6K) and phospho-S6 ribosomal
protein (pS6) in NK-92 cells expressing constitutively active NHE1, inactive NHE1
(NHE1-E262I), or empty vector (EV) treated with pH-controlled media (defining
extracellular pH, or pHe) for 6 or 24 hours. (B) Degranulation of trametinib (MEK
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inhibitor)-treated NK-92 cells against K562 cells, relative to untreated cells (N = 3
wells, X-axis in log2 scale). (C) Representative immunoblots from two independent
experiments assessing phospho-p44/42 MAPK (pERK1/2) in NK-92 cells expressing
NHE1, NHE1-E262I, or EV treated with pH-controlled media for 6 or 24 hours. (D)
Percentage of NHE1-, NHE1-E262I-, or EV-expressing NK-92 cells positive for
intracellular pERK1/2 overtime after interacting with K562 cells (N = 3 wells, two-way
ANOVA with multiple comparisons). * p < 0.05, *** p < 0.001.
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Figure 13. Additional experiment showing elevated target cell-induced ERK
phosphorylation in NHE1-expressing NK-92 cells.
Percentage of NHE1- or EV-expressing NK-92 cells positive for intracellular pERK1/2
after treatment with the MEK inhibitor trametinib or interacting with K562 cells (N = 6
wells, pooled from two independent experiments, unpaired t-test). ** p < 0.01, *** p <
0.001.
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3.7: NHE1 promotes degranulation of NK-92 cells
Degranulation is essential for cytotoxicity. Since NHE1-overexpressing NK-92
cells demonstrated increased degranulation, we focused our mechanistic study on the
characteristics of degranulation. We assessed the degranulation kinetics of the cells and
observed lower percentages of degranulation of NHE1-expressing NK-92 cells at early
time points compared with EV control cells (Figure 14A). However, the rate of
degranulation driven by ectopic NHE1 was higher than EV. After 8 hours, NHE1
expressing cells had the highest level of degranulation compared to either NHE1-E262I
or EV. These differences were observed in biologically replicated studies (Figure 14A).
Although NK cells are known to kill target cells in relatively short time frames in vitro, NK
cells, including NK-92 cells, can kill serially, meaning killing multiple target cells
sequentially (Choi and Mitchison, 2013). For example, NK-92 cells have been shown to
serially kill tumor cells such as K562 cells, with the percentage of killed target cells
increasing continuously over the eight-hour interval (Navarrete-Galvan et al., 2022).
Therefore, it is possible that NHE1-expressing NK-92 cells, although slower to kill than
EV cells at first, achieve higher target cell killing in prolonged assays. The superior level
of degranulation conferred by NHE1 may reflect the enhanced interaction between NK92 cells and their target cells. Indeed, NHE1-overexpressing NK-92 cells were more
likely to form conjugates five hours after co-incubation with target cells than EV or
NHE1-E262I cells (Figure 14B). However, we do not know why there was a delay in the
kinetics of degranulation kinetics in NHE1- or NHE-E262I-expressing NK-92 cells before
the two-hour time point.
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Given the increased degranulation and target cell conjugation conferred by
ectopic NHE1, we sought to determine whether there were differences in immunological
synapses formed by NHE1-expressing or EV NK-92 cells. As noted previously, low pHe
can lead to low pHi, which induces the polarization of lysosomes away from the MTOC in
epithelial cells (Walton et al. 2018). Furthermore, Walton et al. surmised that low pHi
could activate kinesin activity and thereby induce the movement of lysosomes away from
the perinuclear MTOC to the cell periphery. Here, we surmise from this observation that
by analogy, cytotoxic granules in NK-92 cells, which must move toward the MTOC for
degranulation, have diminished ability to move toward the immunologic synapse in acidic
conditions.
Therefore, we studied the immunological synapses formed by NK-92 cells on an
activating antibody-coated surface (Figure 14C and 15). For this assay, NK cellactivating anti-human CD337 (NKp30) antibodies were coated on glass coverslips, and
then NK-92 cells were allowed to adhere with the help of anti-human CD18 antibodies.
Specifically, we assessed the convergence of lytic granules towards the immunological
synapses, which promotes the focused release of cytotoxic proteins and efficient killing
of target cells by NK cells (Hsu et al., 2017b, 2016). Using confocal microscopy with
optical sectioning, we analyzed the horizontal and vertical spread of lytic granules
around the immunological synapses of NK-92 cells (Figure 14D). To assess the
horizontal spread of lytic granules in the direction parallel to the cell-surface contact
plane, we first identified the geometric center (centriole) of perforin-positive lytic granules
using the max-projection image along the Z-axis of the Z-stack images. Then, we
calculated the average distance of individual lytic granules to the geometric center as a
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measurement of the horizontal spread of the lytic granules. A larger average distance
indicates a higher horizontal spread of the lytic granules (hence less convergence)
(Figure 14D, lower left). To assess the vertical spread of lytic granules in the direction
perpendicular to the cell-surface contact plane, we used two different measurements.
First, we measured the area representing perforin-containing lytic granules within each
slice of the Z-stack images using auto-threshold methods. We plotted the obtained area
against the distance of the slices from the cell-surface contact plane (immunological
synapse). Assuming a normal distribution of lytic granules from the contact plane, we
fitted the plotted curve with a Gaussian curve and calculated the best fit standard
deviation (SD) of the resulting Gaussian curve. A larger SD is assumed to represent
more distributed lytic granules along the vertical direction (hence less convergence
toward the immunological synapse) (Figure 14D, lower right). Alternatively, we
calculated the percentage of lytic granules within the first 4 µm above the cell-surface
contact plane within each cell. A higher percentage of lytic granules within the immediate
layers adjacent to the immunological synapse indicates higher synaptic convergence in
the vertical direction. Although we did not identify any significant differences in the
horizontal spread of lytic granules away from their geometric center among NK-92 cells
expressing NHE1, NHE1-E262I, or EV (Figure 14E), we noticed the reduced vertical
spread of lytic granules away from the immunological synapses in NK-92 cells
expressing the constitutively active NHE1 (Figure 14F). These cells also have more
percentage of lytic granules placed around the immunological synapse (Figure 14G).
Therefore, we surmise that NHE1, by increasing pHi, increases the polarization of lytic
granules toward the immunological synapse (and potentially MTOC) and thereby
enhances cytotoxicity. These findings are consistent with the previous observation that
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low pHi drives the polarization of lysosomes away from the MTOC as seen in epithelial
cells (Walton et al., 2018).
To explore transcriptomic changes that could explain NHE1-mediated increased
degranulation in NK-92 cells, we performed QuantSeq 3' mRNA-sequencing to analyze
differences between NHE1 and EV NK-92 cells. We identified 67 genes that were
significantly differentially expressed between NHE1 and EV cells at neutral pHe with a
greater-than-two-fold change and adjusted P-value < 0.05 (Figure 16A and Table 2).
Contrary to expectation, we found that the NHE1-expressing NK-92 cells had decreased
expression of genes containing bindings sites of the STAT family of transcription factors
that are related to the effector function of NK cells (Gotthardt and Sexl, 2017) (Figure
16B). Further, we also noticed the diminished expression of gene sets related to immune
cell functions in NHE1-expressing NK-92 cells (Figure 16C) and downregulation of
genes encoding cytotoxic proteins such as granzyme B (gene symbol GZMB) (Table 2).
However, despite the downregulation at mRNA levels, the protein levels of granzyme B
and perforin, another cytotoxic protein, were increased in NK-92 cells expressing the
constitutively active NHE1 but not the inactive NHE1, as detected by flow cytometry and
immunoblotting (Figure 14H and 14I). The increases in granzyme B and perforin levels
are congruent with the observation that multiple gene sets related to the translational
pathway, such as ribosome biogenesis, were enriched in NHE1-expressing NK-92 cells
compared with EV cells (Figure 14J and Figure 16C). In addition, we also observed
enrichment of Myc target genes (Figure 14J), many of which are related to translational
pathways (Kim et al., 2000) and regulate translational initiation (Singh et al.,
2019).Taken together, these results indicate that the increased cytotoxicity of NHE177

overexpressing NK-92 cells is likely due to increased levels of granzyme B and perforin
as well as enhanced lytic granule polarization, target cell engagement, and
degranulation.
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Figure 14. NHE1 promotes degranulation of NK-92 cells
(A) Degranulation of NK-92 cells expressing constitutively active NHE1, inactive NHE1
(NHE1-E262I), or empty vector (EV) towards K562 cells over time (N = 3 wells,
showing two independent experiments, X-axis in log2 scale, one-way ANOVA). (B)
Conjugate formation between NK-92 cells expressing NHE1, NHE1-E262I, or EV and
K562 cells over time (N = 4 wells, X axis in log2 scale, two-way ANOVA). (C)
Representative Z-projected microscopic images of antibody-activated NK-92 cells
expressing NHE1, NHE1-E262I, or EV, with fluorescent labeling of nuclei (DAPI, cyan)
and F-actin (phalloidin, magenta), and immunofluorescence of perforin (yellow). Scale:
10 µm. (D) Schematic representation of the horizontal (X-Y) and vertical (Z) spread of
lytic granules around the immunological synapse formed between NK-92 cells and
antibody-coated activating surface. (E) Average X-Y distance of perforin-positive lytic
granules to their geometric center within NK-92 cells expressing NHE1, NHE1-E262I,
or EV in arbitrary units (AU) (N = 15 cells from in 4 wells from 2 independent
experiments). (F) Distribution of areas of perforin-positive lytic granules across the Zaxis in NK-92 cells expressing NHE1, NHE1-E262I, or EV fitted with a Gaussian
curve, with standard deviation (SD) from the calculated best fit (F-test) (N = 15 cells
from in 4 wells from 2 independent experiments, shaded bars represent SEM). (G)
Percentage of perforin-positive lytic granules within the first 4 µm above the cellsurface contact plane (N = 15 cells from in 4 wells from 2 independent experiments,
one-way ANOVA with multiple comparisons). (H) Intracellular granzyme B and perforin
levels in NHE1- or NHE1-E262I-expressing NK-92 cells relative to EV controls
(granzyme B: N = 7 from two independent experiments, perforin: N = 4, one-way
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ANOVA with multiple comparisons). (I) Representative immunoblots of granzyme B
and perforin 1 in NK-92 cells expressing NHE1, NHE1-E262I or EV in normal cell
culture media (pH 7.4). Numbers below gel images indicate intensity of the
corresponding band relative to the loading control (tubulin) and normalized to that of
NK-92-EV samples (N = 3 wells). (J) Enrichment plots of two representative gene sets
enriched in NHE1-expressing NK-92 cells compared with empty vector cells. * p <
0.05, ** p < 0.01, *** p < 0.001.
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Figure 15. Representative microscopic images from the study of immunological
synapses of NK-92 cells.
(A) Three-dimensional (3D) reconstruction of confocal microscopic images of
antibody-activated NK-92 cells expressing NHE1, NHE1-E262I, or EV, with
fluorescent labeling of nuclei (DAPI, cyan) and F-actin (phalloidin, magenta), and
immunofluorescence of perforin (yellow). (B) First-slice (immediately above the cellsurface contact plane) images of the cells. Scale: 10 µm.
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Figure 16. Quant-seq analysis of Na+/H+-exchanger 1 (NHE1)-expressing NK-92
cells
(A) Heatmap of all differentially expressed genes with log2(fold change) > 1 and p <
0.05 (N = 3 samples). (B) Enrichment of gene sets representing potential targets of
regulation by transcription factors or microRNAs (curated in category C3 of the
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MSigDB) in genes upregulated in NHE1 (upper) or EV (lower) cells. (C) Enriched gene
sets in NHE1- or EV-expressing NK-92 cells.
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Table 3. Differentially expressed genes between Na+/H+-exchanger 1 (NHE1)expressing and empty vector NK-92 cells, ranked by log2(fold change).

Gene symbol

log2(fold change)

Average
log expression

t

P value

Adjusted
P value

SCO2

5.103573

-0.54501915

4.9902

0.00041

0.02475

ITGB1P1

4.645597145

0.484581501

5.2806

0.00026

0.01875

TRIM9

3.169068388

0.775067549

6.735

3.23E-05

0.00538

SVIL

2.499327608

0.405048831

5.313

0.00025

0.01827

KDM5B

2.34695473

3.309948129

8.4944

3.70E-06

0.00132

S100A8

1.736219927

7.360837922

23.245

1.07E-10

6.52E-07

NTRK2

1.563991339

2.712950259

6.8571

2.75E-05

0.00471

SMAD3

1.551572451

3.673007692

8.9738

2.17E-06

0.00101

MYO1E

1.50557722

3.191612883

8.6614

3.06E-06

0.00116

FMNL2

1.500968015

1.470190094

5.1468

0.00032

0.02152

GABRB3

1.419259878

4.48649066

9.8335

8.80E-07

0.00063

RBM41

1.367224103

1.631172352

4.5659

0.00081

0.03602

P2RX5

1.343992755

2.919964421

5.9879

9.11E-05

0.01045

PDGFRL

1.326987156

1.624479413

4.2176

0.00144

0.04843

ANO3

1.291170467

2.188159282

4.288

0.00128

0.04678

INHBA

1.283301556

2.644965289

5.6657

0.00015

0.01363

TMEM217

1.136889448

1.591037007

4.2394

0.00139

0.04822

ZSCAN5A

1.088095058

2.106319022

4.4957

0.00091

0.03803

DENND1A

1.041340238

2.245006385

4.2063

0.00147

0.04843

SLAMF8

1.031124736

3.418922056

5.7039

0.00014

0.01339

GZMH

-1.004760947

4.827554777

-8.663

3.06E-06

0.00116

OSBPL5

-1.011549762

2.966947793

-5.5213 0.00018

0.01491

TIMP1

-1.014456484

4.939141088

-7.1161 1.96E-05

0.00382

CTLA4

-1.020656956

4.479071999

-9.1913 1.72E-06

0.00087

SEPTIN8

-1.029990324

3.645980533

-5.5743 0.00017

0.01457

IL27RA

-1.051969557

4.784294875

-9.5035 1.23E-06

0.00072
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SERPINB6

-1.058408586

2.899745041

-5.5187 0.00018

0.01491

RUNX1T1

-1.10608903

4.891450744

-7.7686 8.67E-06

0.00245

GZMB

-1.115769822

10.29985992

-25.422 4.08E-11

4.96E-07

TET2

-1.122959269

1.776029623

-4.1829 0.00153

0.0486

TREM1

-1.188254708

3.782253423

-7.1703 1.83E-05

0.00377

SEMA4A

-1.218369696

2.732994271

-5.4097 0.00021

0.01636

LILRA2

-1.255456626

2.966749373

-4.872

0.00049

0.02775

MSANTD3-TMEFF1

-1.279677297

2.443152468

-4.8564 0.00051

0.02825

ADTRP

-1.290842741

3.465986165

-7.6557 9.94E-06

0.00252

DMKN

-1.29132268

2.498078778

-5.2083 0.00029

0.02036

CD160

-1.397084235

4.336829466

-8.0044 6.53E-06

0.00194

FCRL4

-1.414813415

2.976854057

-6.3475 5.48E-05

0.00757

CLU

-1.449939048

7.120337445

-17.013 3.04E-09

1.23E-05

LINC01881

-1.481100897

1.373177843

-4.4472 0.00099

0.03964

HACD4

-1.489528241

1.759461857

-5.2715 0.00026

0.01879

KIAA0930

-1.527637008

2.025573185

-5.1108 0.00034

0.02216

SPINK5

-1.549607724

4.515102644

-11.808 1.38E-07

0.00021

CD86

-1.640925194

2.801591861

-6.5039 4.42E-05

0.00675

LINGO1

-1.736364002

1.630969384

-5.4775 0.00019

0.01528

AC012254.2

-1.772455825

1.960333864

-4.5319 0.00086

0.03732

IL1R1

-1.849176197

1.039660098

-4.975

0.025

ALDH1L1

-1.922106282

0.658622937

-4.7772 0.00058

0.02976

CCR7

-2.0607137

2.490946293

-8.9082 2.33E-06

0.00101

DNASE2

-2.137496925

2.94845012

-10.842 3.30E-07

0.00043

NRXN3

-2.202915542

1.91386585

-6.6192 3.78E-05

0.00604

IL18RAP

-2.289036176

2.415404288

-8.0743 6.01E-06

0.00187

IL1R2

-2.366774096

0.584346302

-5.2196 0.00029

0.02012

BTBD3

-2.471931273

0.811450097

-4.8021 0.00055

0.02914

ARAP3

-2.526530593

-0.420092111

-4.2619 0.00134

0.04762

NFE2

-2.6336511

-0.185243961

-4.814

0.02914

HOMER1

-2.816204192

1.869948617

-9.7079 9.99E-07
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0.00042

0.00054

0.00064

NAALADL2

-2.831367255

-0.100897893

-4.2901 0.00128

0.04678

NCR2

-2.838997312

1.111831082

-7.4424 1.30E-05

0.00309

SPTA1

-2.855696784

-0.877266296

-4.8007 0.00055

0.02914

SLPI

-2.856383197

-1.001697612

-4.6074 0.00076

0.03499

ST7

-2.942593185

0.217468515

-5.9286 9.93E-05

0.01107

TLL1

-3.311098714

-0.909809451

-5.4238 0.00021

0.01622

GLP1R

-3.806179709

0.954122542

-8.1236 5.67E-06

0.00181

ANGPT1

-3.991621564

0.68948328

-8.387

4.18E-06

0.00145

NR2F2

-4.206919832

0.034316434

-6.8947 2.62E-05

0.00454

AP003419.1

-5.897449991

-2.012793747

-10.658 3.92E-07

0.00043
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3.8: NHE1 enhances the antitumor activity of NK-92MI cells in vivo
Having observed the enhanced cytotoxicity of NHE1-overexpressing NK-92 cells
in vitro, we proceeded to test the effect of NHE1 on the antitumor activity of effector
immune cells in an animal model. Instead of the conventional NK-92 cells that are IL-2
dependent, we used NK-92MI cells, which are NK-92 cells that stably express human IL2 and were reported to have better performance in vivo (Tam et al., 1999). We confirmed
that NHE1-overexpressing NK-92MI cells had increased cytotoxicity in vitro as compared
to the EV control (Figure 17). We treated NSG mice bearing WM3629 xenografts with
either NHE1-overexpressing NK-92MI cells, EV control cells, or no-cell-transfer controls
(PBS) by intravenous injection. We observed in two independent experiments that ACT
with NK-92MI cells reduced tumor growth compared to no cell transfer controls (Figure
18A and 18C). Moreover, NHE1-overexpressing NK-92MI cells were statistically
significantly more effective than EV NK-92MI cells at slowing tumor growth and reducing
tumor weight at the endpoint of the experiments (Figure 18B and 18D). If NK-92MI cells
reduced tumor growth by their cytotoxic activities, we expect to find evidence of higher
tumor cell death in animals treated with EV or NHE1 NK-92MI cells compared with nocell-transfer controls. Indeed, we observed increased apoptosis in tumors treated with
NHE1-expressing NK-92MI cells compared with no-cell-transfer controls (Figure 18E
and 18F).
In aggregate, our study indicates that ectopic NHE1 confers higher pHi in NK-92
cells, which engage target cells more effectively and have increased degranulation and
cytotoxicity in vitro. The increase in degranulation correlated with a larger percentage of
cytotoxic granules polarized toward the immunological synapse and increased protein
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expression of cytolytic proteins. Most importantly, Consistent with the increased in vitro
target engagement and cytotoxicity, overexpression of NHE1 can enhance adoptively
transferred NK-92MI cell function in vivo, leading to reduced tumor growth in treated
mice. These observations provide a proof of concept that metabolic engineering of
cytotoxic immune cells could be an avenue to increase the clinical effectiveness of ACT
with engineered lymphocytes.
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Figure 17. NHE1 enhances in vitro cytotoxicity of NK-92MI.
In vitro cytotoxicity of NK-92MI cells expressing NHE1 or EV against WM3629 cells in
pH-controlled media (defining extracellular pH, or pHe) (N = 6, unpaired t-test). *** p <
0.001.
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Figure 18. NHE1 enhances in vivo cytotoxicity of NK-92MI cells.
(A) and (C) Tumor volume of mice with WM3629 xenografts treated with intravenous PBS (no
cell transfer control) or NK-92MI cells expressing constitutively active NHE1 or empty vector
(EV) control (N = 7 for all groups in A, N = 8, 9, and 9 for PBS, EV, and NHE1 groups in B,
respectively; two-way ANOVA). (B) and (D) Tumor weight of the mice in (A) and (C) at
endpoints (N = 7 for all groups in B, N = 8, 9, and 9 for PBS, EV, and NHE1 groups in D,
respectively; unpaired t-test). (E) Representative microscopic images of cleaved caspase 3stained tumor slices from mice treated with PBS or NK-92MI cells expressing NHE1 or EV.
Scale: 40 μm. (F) Quantification of the percentage of cleaved caspase 3-positive area in
images in E (N = 12 random fields from 3 mice for each group, one-way ANOVA with multiple
comparisons). * p < 0.05, ** p < 0.01, *** p < 0.001.
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CHAPTER 4: Conclusions and Future Directions
Although ACT has transformed cancer immunotherapy with successful
applications such as CAR T-cell therapy, many cancer patients, especially those with
solid tumors, remain unresponsive to such therapies (Hou et al., 2019; Marofi et al.,
2021). A significant challenge to ACT is the immunosuppressive TME, with acidity likely
being a major metabolic factor limiting the antitumor activity of immune cells. Targeting
the acidic TME is thus a promising approach to enhance the efficacy of immunotherapy.
One method to target the acidic TME is the oral administration of NaHCO3, which leads
to elevated blood pH and has been shown by magnetic resonance imaging (MRI) to
increase intratumoral pH in vivo (Gallagher et al., 2008). Furthermore, systemic
neutralization by bicarbonate boosted the efficacy of ICB or ACT in some animal models
(Pilon-Thomas et al., 2016; Pötzl et al., 2017). However, systemic neutralization may
also benefit tumor cells experiencing acidosis by activating acid-blunted, pro-tumorigenic
signaling pathways such as mTORC1, as we reported previously (Walton et al., 2018).
Specifically, we found that systemic buffering with oral NaHCO3 resulted in increased
pS6, a mTORC1 downstream effector, in HCT116 colon and MCF7 breast tumor
xenografts in immunocompromised mice, but the previous systemic buffering attempts
were not designed to test an effect on tumor immunity. Given the clinical observation
that NaHCO3 enhanced the antitumor activity of transarterial chemoembolization in
patients with HCC (Chao et al., 2016), we sought to determine whether systemic
buffering would enhance the effect of the immune checkpoint inhibitor anti-PD1 using an
aggressive MYC-inducible HCC mouse model (Beer et al., 2004). Surprisingly, we
found that NaHCO3 increased mTORC1 activity as determined by pS6
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immunohistochemistry and seemingly negated the effect of anti-PD1 in curbing tumor
growth. In this case, enhanced tumor mTORC1, which is sufficient to drive transgenic
mouse HCC tumorigenesis (Menon et al., 2012), is surmised to allow tumor growth to
dominate over any potential beneficial effect on antitumor immunity. As such, systemic
buffering as an anti-cancer approach cannot be expected to be generalizable. Hence,
we sought to approach tumor acidity by metabolic engineering of immune effector cells.
Our results with NHE1-overexpressing NK-92 cells suggest that it is possible to mitigate
the immunosuppressive effect of tumor acidity by specifically engineering immune cells
to resist low pH. This targeted approach reduces the risk of increasing tumor mTORC1
activity and promoting tumor growth through systemic buffering strategies.
We reasoned that if low pH blunts mTORC1, which is required for T and NK cell
activity (Donnelly et al., 2014; Pollizzi et al., 2015, p. 8; Wang et al., 2018), then
increasing mTORC1 activity by expressing a constitutively active RHEB would enhance
NK-92 cell cytotoxicity. Indeed, we found that the RHEB-mediated increase in mTORC1
could enhance degranulation and in vitro cytotoxicity of NK-92 cells. Given this
observation, we hypothesized that increasing pHi would increase mTORC1, thereby
enhancing the cytotoxicity of NK-92 cells. We hypothesize that the ectopic expression of
acid extruder proteins, which are known to alkalinize the cytoplasm of cells (Parks et al.,
2013), would (1) enhance pHi, (2) increase mTORC1 activity, and (3) elevate
cytotoxicity. We then tested the effects of ectopic expression of acid extruder proteins
NHE1 and CA9 in NK-92 cells as an ACT model.
As an acid extruder protein that removes intracellular acid, NHE1 alkalinizes the
pHi of NK-92 cells when overexpressed. Others have also suggested that NHE1 was
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involved in the alkalinization of the cytoplasm of tumor cells (Busco et al., 2010).
Although we have shown that epithelial cells in an acidic environment have lowered pHi
and blunted mTORC1 activity due to dispersion of lysosomes (Walton et al., 2018),
NHE1-expressing NK-92 cells, despite having heightened pHi, did not show elevated
mTORC1 activity. Conversely, we found that ectopic expression of the acid extruder
protein CA9 did not increase pHi but elevated mTORC1 without enhancing NK-92
cytotoxicity. Whether and how mTORC1 affects lytic granule function in NK cells is
unknown and remains to be established. However, it is possible that mTORC1 activity in
NK-92 cells, rather than only responding to pHi, responds additionally to changes in pHe
with the help of cell surface pH-sensing proteins such as pH-sensing GPCRs (Justus et
al., 2013; Radu et al., 2005). For example, TDAG8, a pH-sensing GPCR, is expressed in
immune cells, including lymphoid cells and macrophages, and potentially mediates the
inhibitory effect of the acidic TME on tumor-infiltrating macrophages (Mogi et al., 2009).
Although we observed expression of TDAG8 in NK-92 cells by Quant-seq (data not
shown), it is unclear whether it is involved in pHe sensing by these cells. However, we
did not determine the effects of CA9 or NHE1 expression on the activity of these
GPCRs. Regardless of how acidic pHe is mechanistically sensed to reduce mTORC1
activity, the level of mTORC1 activity in NK-92 cells appears to be dissociated from
cytolytic activity, which may depend on other effects of pHi on lytic granule biology.
Although NHE1 does not activate mTORC1 in NK-92 cells, we found that it
activated ERK. It has been reported that NHE1 colocalizes with ERK2 (HendusAltenburger et al., 2016). In addition, NHE1 can be phosphorylated by ERK at its
cytoplasmic tail, activating its ion exchanger activity (Fliegel, 2019). Interestingly, a
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recent study suggested the existence of a positive feedback loop between the
phosphorylation of NHE1 and ERK in BRAFV600E-positive glioblastoma cells (Li et al.,
2022). Consistent with the finding in the previous work that pharmacological inhibition of
NHE1 did not completely block ERK phosphorylation, we showed that a mutant NHE1
without ion exchanger activity still activated ERK. This observation indicates that the
increased ERK phosphorylation in NHE1-expressing NK-92 cells is independent of the
ion exchanger activity. Instead, it might be due to protein-protein interaction at the
cytoplasmic tail domain of NHE1 (Yan et al., 2001, p. 1), which is likely not affected by
the mutation. Further studies are needed to elucidate whether such a positive feedback
loop between NHE1 and ERK exists in immune effector cells and whether the
constitutively active NHE1 used in our study maintains a high phosphorylation level.
Mechanistically, our results suggest that NHE1 promotes the degranulation of
NK-92 cells towards target cells. Degranulation is a crucial component of the effector
function of NK cells and cytotoxic T cells, during which lytic granules containing cytotoxic
proteins are released to lyse target cells (Paul and Lal, 2017). While the exact
mechanism for NHE1 to affect degranulation is not fully understood, our results suggest
two possible explanations. First, NHE1 may alter the trafficking of lytic granules towards
target cells, thereby altering the kinetics of degranulation and the formation of
immunological synapses, as we observed. Supporting this notion is the trend of reduced
vertical spread of lytic granules in NK-92 cells expressing NHE1. The trafficking of lytic
granules during the degranulation of NK cells involves the concerted reorganization of
actin and microtubule cytoskeletons and the activity of their corresponding motor
proteins (Ben-Shmuel et al., 2021). NHE1 is known to physically interact with the ERM
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family of actin-binding proteins (Denker et al., 2000) and regulate cellular motility (Stock
and Schwab, 2006). However, whether NHE1 alters the actin-dependent trafficking
during the degranulation of NK cells remains undetermined. We also reported previously
that intracellular alkalinization led to microtubule-based translocation of lysosomes
towards the MTOC (Walton et al., 2018), which is in the same direction as lytic granule
movements during degranulation. Therefore, it is also possible that NHE1 potentiates
NK-92 degranulation by promoting the trafficking of lytic granules toward target cells
(Figure 19). However, further studies are needed to understand how the microtubule
trafficking system senses pHi. For example, albeit technically challenging, genetic
manipulation of kinesins or dyneins in NK-92 cells may provide mechanistic insight into
how NHE1 may affect lytic granule trafficking as was performed in epithelial cells
(Walton et al., 2018). Second, NHE1 may prepare NK cells for effective degranulation by
promoting the accumulation of cytotoxic proteins such as granzyme B and perforin. We
found that NHE1-expressing NK-92 cells had elevated levels of these proteins, with
concomitant enrichment of gene sets related to the translational pathway.
As a regulator of pHi, NHE1 may also modulate metabolic processes sensitive to
pHi. For example, it has been predicted that higher pHi promotes oxidative and glycolytic
metabolism in metabolically active cells such as cancer cells (Persi et al., 2018).
Interestingly, a recent study showed that pHi alkalinization conferred by acid extruder
proteins such as MCT4 or NHE1 was sufficient to promote carbon metabolism in normal
hematopoietic cells and leukemia cells (Man et al., 2022). While we did not study the
metabolic profile of NHE1-expressing NK-92 cells, we observed enrichment of Myc
target genes in these cells. In addition to its role in translation, Myc is also a regulator of
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cellular metabolism that controls the expression of metabolic enzymes and transporters
(Loftus et al., 2018; Osthus et al., 2000). We speculate that such metabolic
reprogramming may provide NHE1-expressing NK-92 cells an advantage in the
metabolically challenging TME, as Myc is documented to drive IL2-dependent NK cell
function in vivo (Loftus et al., 2018).
Our study provides mechanistic support for the metabolic engineering of immune
cells in ACT. Others have already demonstrated the technical feasibility of coexpressing
a CAR and a second protein, such as a chemokine, in T cells for enhanced antitumor
activity (Di Stasi et al., 2009). Therefore, it would be possible to coexpress metabolic
regulators, such as NHE1, with CAR in T cells or NK cells to help them overcome the
immunosuppressive effect of acidity within the TME. Our choice of overexpressing a
constitutively active NHE1 offers two advantages for use in CAR T-cells. First, the
constitutively active NHE1 bypasses the pH sensing of wild-type NHE1, thereby allowing
sustained activity of NHE1 while eliminating the need for overexpressing additional
proteins involved in pH-sensing, such as CHP1 (Dong et al., 2021). Second, while we
and others have shown that directly activating mTORC1 in immune cells boosts their
cytotoxicity, sustained activation of mTORC1 prevents memory differentiation of
therapeutic T cells, potentially limiting their long-term efficacy (Veliça et al., 2015). Our
results suggest that NHE1 does not activate mTORC1 in NK-92 cells. However, more
research is needed to assess the effect of NHE1 on T cell differentiation before applying
it to CAR T-cells. A systematic assessment of animals receiving NHE1-expressing
immune cells (NK, T, or CAR T-cells) with higher antitumor activity is necessary to
determine the safety profile of such cells before applying them to clinical settings.
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The current study has several limitations. First, we used NK-92 cells as a model
for immune effector cells. While NK-92 cells share similar killing mechanisms as primary
NK cells, it remains undetermined whether the effect of overexpressing NHE1 can be
reproduced in primary NK cells. Further, despite the documented similarity between NK
cells and cytotoxic T cells regarding effector functions and intracellular signaling (NarniMancinelli et al., 2011; Uzhachenko and Shanker, 2019), it will be necessary to test
whether NHE1 enhances the antitumor activity of cytotoxic T cells. Second, while we
observed a correlation between increased antitumor activity and enhanced degradation
in NHE1-overexpressing NK-92 cells, the exact mechanism underlying such a
correlation remains to be conclusively determined. Hence, future studies are necessary
to focus on the mechanisms by which NHE1 affects granule trafficking and protein
synthesis, which likely contribute to the increased cytotoxicity of NHE1-expressing NK92 cells.
In summary, these findings demonstrate the feasibility of metabolic engineering
immune cells to overcome inhibition in the TME. Furthermore, the metabolic engineering
approach can potentially be combined with ACT to enhance its efficacy against solid
tumors, where the TME is a significant cause of immune inhibition.
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Figure 19. Schematic representation of the proposed model for NHE1 to
enhance NK-92 cytolytic activity.
When NK-92 cells (green) engage tumor cells (red), the former polarize their cytolytic
granules towards the latter to prepare for degranulation. This polarization is achieved
by translocation of the MTOC towards the NK-92-tumor cell interface (immunological
synapse), followed by the movement of individual lytic granules along microtubules
towards the MTOC. However, the acidic conditions in the TME lead to acidified pHi
and disrupt the organized movement of lytic granules, reducing the cytolytic activity of
NK-92 cells. By overexpressing NHE1, an acid extruder protein that facilitates the
removal of intracellular acid, NK-92 cells can maintain a higher pHi in acidic
conditions, thereby preserving the organized movement of lytic granules during
degranulation, leading to higher cytolytic activity (figure created with BioRender.com).
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